{ "version": "2.2", "instance": { "tlx-20260630.htm tlx-20260630_d2.htm": { "nsprefix": "tlx", "nsuri": "http://telixpharma.com/20260630", "dts": { "inline": { "local": [ "tlx-20260630.htm", "tlx-20260630_d2.htm" ] }, "schema": { "local": [ "tlx-20260630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/rol_ifrs_ea-dim_2025-03-27.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/rol_full_ifrs-dim_2025-03-27.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd", "https://xbrl.sec.gov/country/2025/country-2025.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd" ] }, "calculationLink": { "local": [ "tlx-20260630_cal.xml" ] }, "definitionLink": { "local": [ "tlx-20260630_def.xml" ], "remote": [ "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/dim_ifrs_ea_2025-03-27_role-995000.xml", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/dim_full_ifrs_2025-03-27_role-995000.xml" ] }, "labelLink": { "local": [ "tlx-20260630_lab.xml" ] }, "presentationLink": { "local": [ "tlx-20260630_pre.xml" ] } }, "keyStandard": 154, "keyCustom": 60, "axisStandard": 15, "axisCustom": 0, "memberStandard": 37, "memberCustom": 13, "hidden": { "total": 4, "http://xbrl.sec.gov/dei/2025": 4 }, "contextCount": 215, "entityCount": 1, "segmentCount": 51, "elementCount": 357, "unitCount": 7, "baseTaxonomies": { "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full": 770, "http://xbrl.sec.gov/dei/2025": 11 }, "report": { "R1": { "role": "http://telixpharma.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630.htm", "first": true, "unique": true } }, "R2": { "role": "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome", "longName": "9952151 - Statement - Interim consolidated statement of comprehensive income", "shortName": "Interim consolidated statement of comprehensive income", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "ifrs-full:DisclosureOfGeographicalAreasExplanatory", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:IncomeTaxExpenseContinuingOperations", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "unique": true } }, "R3": { "role": "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition", "longName": "9952152 - Statement - Interim consolidated statement of financial position", "shortName": "Interim consolidated statement of financial position", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ifrs-full:TradeAndOtherCurrentReceivables", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "unique": true } }, "R4": { "role": "http://telixpharma.com/role/Interimconsolidatedstatementofchangesinequity", "longName": "9952153 - Statement - Interim consolidated statement of changes in equity", "shortName": "Interim consolidated statement of changes in equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-21", "name": "ifrs-full:Equity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-22", "name": "ifrs-full:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "unique": true } }, "R5": { "role": "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows", "longName": "9952154 - Statement - Interim consolidated statement of cash flows", "shortName": "Interim consolidated statement of cash flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ReceiptsFromSalesOfGoodsAndRenderingOfServices", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:ReceiptsFromSalesOfGoodsAndRenderingOfServices", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true } }, "R6": { "role": "http://telixpharma.com/role/Corporateinformation", "longName": "9952155 - Disclosure - Corporate information", "shortName": "Corporate information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true } }, "R7": { "role": "http://telixpharma.com/role/Materialaccountingpolicyinformation", "longName": "9952156 - Disclosure - Material accounting policy information", "shortName": "Material accounting policy information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true } }, "R8": { "role": "http://telixpharma.com/role/Segmentreporting", "longName": "9952157 - Disclosure - Segment reporting", "shortName": "Segment reporting", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true } }, "R9": { "role": "http://telixpharma.com/role/Profitandlossinformation", "longName": "9952158 - Disclosure - Profit and loss information", "shortName": "Profit and loss information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "tlx:DisclosureOfProfitAndLossInformationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "tlx:DisclosureOfProfitAndLossInformationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true } }, "R10": { "role": "http://telixpharma.com/role/Intangibleassets", "longName": "9952159 - Disclosure - Intangible assets", "shortName": "Intangible assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true } }, "R11": { "role": "http://telixpharma.com/role/Borrowings", "longName": "9952160 - Disclosure - Borrowings", "shortName": "Borrowings", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfBorrowingsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfBorrowingsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true } }, "R12": { "role": "http://telixpharma.com/role/Contractualmaturitiesoffinancialliabilities", "longName": "9952161 - Disclosure - Contractual maturities of financial liabilities", "shortName": "Contractual maturities of financial liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true } }, "R13": { "role": "http://telixpharma.com/role/Equity", "longName": "9952162 - Disclosure - Equity", "shortName": "Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true } }, "R14": { "role": "http://telixpharma.com/role/Fairvalue", "longName": "9952163 - Disclosure - Fair value", "shortName": "Fair value", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFairValueMeasurementExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFairValueMeasurementExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true } }, "R15": { "role": "http://telixpharma.com/role/ContingentliabilitiesandCommitments", "longName": "9952164 - Disclosure - Contingent liabilities and Commitments", "shortName": "Contingent liabilities and Commitments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true } }, "R16": { "role": "http://telixpharma.com/role/Eventsoccurringafterthereportingperiod", "longName": "9952165 - Disclosure - Events occurring after the reporting period", "shortName": "Events occurring after the reporting period", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true } }, "R17": { "role": "http://telixpharma.com/role/MaterialaccountingpolicyinformationPolicies", "longName": "9955511 - Disclosure - Material accounting policy information (Policies)", "shortName": "Material accounting policy information (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true } }, "R18": { "role": "http://telixpharma.com/role/SegmentreportingTables", "longName": "9955512 - Disclosure - Segment reporting (Tables)", "shortName": "Segment reporting (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true } }, "R19": { "role": "http://telixpharma.com/role/ProfitandlossinformationTables", "longName": "9955513 - Disclosure - Profit and loss information (Tables)", "shortName": "Profit and loss information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true } }, "R20": { "role": "http://telixpharma.com/role/IntangibleassetsTables", "longName": "9955514 - Disclosure - Intangible assets (Tables)", "shortName": "Intangible assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true } }, "R21": { "role": "http://telixpharma.com/role/BorrowingsTables", "longName": "9955515 - Disclosure - Borrowings (Tables)", "shortName": "Borrowings (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true } }, "R22": { "role": "http://telixpharma.com/role/ContractualmaturitiesoffinancialliabilitiesTables", "longName": "9955516 - Disclosure - Contractual maturities of financial liabilities (Tables)", "shortName": "Contractual maturities of financial liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true } }, "R23": { "role": "http://telixpharma.com/role/EquityTables", "longName": "9955517 - Disclosure - Equity (Tables)", "shortName": "Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true } }, "R24": { "role": "http://telixpharma.com/role/ContingentliabilitiesandCommitmentsTables", "longName": "9955518 - Disclosure - Contingent liabilities and Commitments (Tables)", "shortName": "Contingent liabilities and Commitments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "tlx:DisclosureOfCommitmentsContractualObligationsExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "tlx:DisclosureOfCommitmentsContractualObligationsExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true } }, "R25": { "role": "http://telixpharma.com/role/MaterialaccountingpolicyinformationDetails", "longName": "9955519 - Disclosure - Material accounting policy information (Details)", "shortName": "Material accounting policy information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true }, "uniqueAnchor": null }, "R26": { "role": "http://telixpharma.com/role/SegmentreportingScheduleofSegmentPerformanceDetails", "longName": "9955520 - Disclosure - Segment reporting - Schedule of Segment Performance (Details)", "shortName": "Segment reporting - Schedule of Segment Performance (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "ifrs-full:DisclosureOfGeographicalAreasExplanatory", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-35", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "ix:continuation", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "unique": true } }, "R27": { "role": "http://telixpharma.com/role/SegmentreportingScheduleofReconciliationofSegmentAdjustedEBITDAtoProfitLossBeforeIncomeTaxesDetails", "longName": "9955521 - Disclosure - Segment reporting - Schedule of Reconciliation of Segment Adjusted EBITDA to Profit/Loss Before Income Taxes (Details)", "shortName": "Segment reporting - Schedule of Reconciliation of Segment Adjusted EBITDA to Profit/Loss Before Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "tlx:AdjustedEarningsLossBeforeInterestTaxDepreciationAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "ix:continuation", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-41", "name": "ifrs-full:GeneralAndAdministrativeExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "ix:continuation", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "unique": true } }, "R28": { "role": "http://telixpharma.com/role/SegmentreportingNarrativeDetails", "longName": "9955522 - Disclosure - Segment reporting - Narrative (Details)", "shortName": "Segment reporting - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:EmployeeBenefitsExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "tlx:DisclosureOfDetailedInformationAboutEmploymentCostsTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-41", "name": "ifrs-full:EmployeeBenefitsExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "unique": true } }, "R29": { "role": "http://telixpharma.com/role/SegmentreportingScheduleofOperatingSegmentAssetsandLiabilitiesDetails", "longName": "9955523 - Disclosure - Segment reporting - Schedule of Operating Segment Assets and Liabilities (Details)", "shortName": "Segment reporting - Schedule of Operating Segment Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:Assets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "ix:continuation", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:AdditionsToNoncurrentAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "ix:continuation", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "unique": true } }, "R30": { "role": "http://telixpharma.com/role/SegmentreportingScheduleofGeographicalInformationDetails", "longName": "9955524 - Disclosure - Segment reporting - Schedule of Geographical Information (Details)", "shortName": "Segment reporting - Schedule of Geographical Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "ifrs-full:DisclosureOfGeographicalAreasExplanatory", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "unique": true } }, "R31": { "role": "http://telixpharma.com/role/ProfitandlossinformationScheduleofRevenuefromContractswithCustomersDetails", "longName": "9955525 - Disclosure - Profit and loss information - Schedule of Revenue from Contracts with Customers (Details)", "shortName": "Profit and loss information - Schedule of Revenue from Contracts with Customers (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:Revenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:Revenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true } }, "R32": { "role": "http://telixpharma.com/role/ProfitandlossinformationScheduleofEmploymentCostsDetails", "longName": "9955526 - Disclosure - Profit and loss information - Schedule of Employment Costs (Details)", "shortName": "Profit and loss information - Schedule of Employment Costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:WagesAndSalaries", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "tlx:DisclosureOfDetailedInformationAboutEmploymentCostsTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "tlx:SalesCommissions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "tlx:DisclosureOfDetailedInformationAboutEmploymentCostsTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "unique": true } }, "R33": { "role": "http://telixpharma.com/role/ProfitandlossinformationNarrativeDetails", "longName": "9955527 - Disclosure - Profit and loss information - Narrative (Details)", "shortName": "Profit and loss information - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:WagesAndSalaries", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "tlx:DisclosureOfDetailedInformationAboutEmploymentCostsTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-88", "name": "tlx:NumberOfInitialTherapeuticPrograms", "unitRef": "product", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "unique": true } }, "R34": { "role": "http://telixpharma.com/role/ProfitandlossinformationScheduleofDepreciationandamortizationDetails", "longName": "9955528 - Disclosure - Profit and loss information - Schedule of Depreciation and amortization (Details)", "shortName": "Profit and loss information - Schedule of Depreciation and amortization (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:AmortisationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "tlx:ScheduleOfDisclosureOfDepreciationAndAmortizationTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:AmortisationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "tlx:ScheduleOfDisclosureOfDepreciationAndAmortizationTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true } }, "R35": { "role": "http://telixpharma.com/role/ProfitandlossinformationScheduleofOtherIncomeDetails", "longName": "9955529 - Disclosure - Profit and loss information - Schedule of Other Income (Details)", "shortName": "Profit and loss information - Schedule of Other Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:OtherIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "tlx:DisclosureOfOtherIncomeTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true }, "uniqueAnchor": null }, "R36": { "role": "http://telixpharma.com/role/ProfitandlossinformationScheduleofFinanceCostsDetails", "longName": "9955530 - Disclosure - Profit and loss information - Schedule of Finance Costs (Details)", "shortName": "Profit and loss information - Schedule of Finance Costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "tlx:UnwindOfDiscount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "tlx:DisclosureOfDetailedInformationAboutFinanceCostsTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:InterestExpenseOnLeaseLiabilities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "tlx:DisclosureOfDetailedInformationAboutFinanceCostsTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "unique": true } }, "R37": { "role": "http://telixpharma.com/role/IntangibleassetsDetails", "longName": "9955531 - Disclosure - Intangible assets (Details)", "shortName": "Intangible assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:IntangibleAssetsAndGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-21", "name": "ifrs-full:IntangibleAssetsAndGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "unique": true } }, "R38": { "role": "http://telixpharma.com/role/BorrowingsNarrativeDetails", "longName": "9955532 - Disclosure - Borrowings - Narrative (Details)", "shortName": "Borrowings - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-147", "name": "ifrs-full:BondsIssued", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-147", "name": "ifrs-full:BondsIssued", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true } }, "R39": { "role": "http://telixpharma.com/role/BorrowingsScheduleofBorrowingsDetails", "longName": "9955533 - Disclosure - Borrowings - Schedule of Borrowings (Details)", "shortName": "Borrowings - Schedule of Borrowings (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:CurrentSecuredBankLoansReceivedAndCurrentPortionOfNoncurrentSecuredBankLoansReceived", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ifrs-full:CurrentSecuredBankLoansReceivedAndCurrentPortionOfNoncurrentSecuredBankLoansReceived", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true } }, "R40": { "role": "http://telixpharma.com/role/BorrowingsScheduleofConvertibleBondsDetails", "longName": "9955534 - Disclosure - Borrowings - Schedule of Convertible Bonds (Details)", "shortName": "Borrowings - Schedule of Convertible Bonds (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:Borrowings", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-153", "name": "tlx:UnwindOfDiscount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "unique": true } }, "R41": { "role": "http://telixpharma.com/role/BorrowingsScheduleofFairValueHierarchyDetails", "longName": "9955535 - Disclosure - Borrowings - Schedule of Fair Value Hierarchy (Details)", "shortName": "Borrowings - Schedule of Fair Value Hierarchy (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:FinancialLiabilities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-160", "name": "ifrs-full:FinancialLiabilities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "unique": true } }, "R42": { "role": "http://telixpharma.com/role/ContractualmaturitiesoffinancialliabilitiesDetails", "longName": "9955536 - Disclosure - Contractual maturities of financial liabilities (Details)", "shortName": "Contractual maturities of financial liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-3", "name": "ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true } }, "R43": { "role": "http://telixpharma.com/role/EquityScheduleofShareCapitalDetails", "longName": "9955537 - Disclosure - Equity - Schedule of Share Capital (Details)", "shortName": "Equity - Schedule of Share Capital (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:IssuedCapital", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-187", "name": "tlx:DeferredConsiderationIndemnityPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "unique": true } }, "R44": { "role": "http://telixpharma.com/role/EquityNarrativeDetails", "longName": "9955538 - Disclosure - Equity - Narrative (Details)", "shortName": "Equity - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-188", "name": "ifrs-full:WeightedAverageShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-188", "name": "ifrs-full:WeightedAverageShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true } }, "R45": { "role": "http://telixpharma.com/role/EquityScheduleofOtherReservesDetails", "longName": "9955539 - Disclosure - Equity - Schedule of Other Reserves (Details)", "shortName": "Equity - Schedule of Other Reserves (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-4", "name": "ifrs-full:Equity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-193", "name": "ifrs-full:OtherComprehensiveIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "ifrs-full:DisclosureOfReservesAndOtherEquityInterestExplanatory", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "unique": true } }, "R46": { "role": "http://telixpharma.com/role/FairvalueDetails", "longName": "9955540 - Disclosure - Fair value (Details)", "shortName": "Fair value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-206", "name": "tlx:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariablePercent", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-206", "name": "tlx:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariablePercent", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true } }, "R47": { "role": "http://telixpharma.com/role/ContingentliabilitiesandCommitmentsDetails", "longName": "9955541 - Disclosure - Contingent liabilities and Commitments (Details)", "shortName": "Contingent liabilities and Commitments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-212", "name": "ifrs-full:ContractualCapitalCommitments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-212", "name": "ifrs-full:ContractualCapitalCommitments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "span", "div", "div", "div", "td", "tr", "tbody", "table", "div", "div", "div", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tlx-20260630_d2.htm", "first": true, "unique": true } } }, "tag": { "country_AU": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2025", "localname": "AU", "presentation": [ "http://telixpharma.com/role/SegmentreportingScheduleofGeographicalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Australia", "label": "AUSTRALIA" } } }, "auth_ref": [] }, "ifrs-full_AccumulatedDepreciationAndAmortisationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AccumulatedDepreciationAndAmortisationMember", "presentation": [ "http://telixpharma.com/role/IntangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated depreciation", "label": "Accumulated depreciation and amortisation [member]" } } }, "auth_ref": [ "r7", "r277", "r279", "r285", "r286" ] }, "ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill", "crdr": "debit", "presentation": [ "http://telixpharma.com/role/IntangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition of businesses", "label": "Acquisitions through business combinations, intangible assets and goodwill" } }, "en": { "role": { "documentation": "The increase in intangible assets and goodwill resulting from acquisitions through business combinations. [Refer: Total for all business combinations [member]; Intangible assets and goodwill]" } } }, "auth_ref": [ "r280" ] }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://telixpharma.com/role/IntangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions", "label": "Additions other than through business combinations, intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Intangible assets other than goodwill]" } } }, "auth_ref": [ "r21", "r154" ] }, "ifrs-full_AdditionsToNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdditionsToNoncurrentAssets", "crdr": "debit", "presentation": [ "http://telixpharma.com/role/SegmentreportingScheduleofOperatingSegmentAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions to non-current assets", "label": "Additions to non-current assets other than financial instruments, deferred tax assets, net defined benefit assets, and rights arising under insurance contracts" } }, "en": { "role": { "documentation": "The amount of additions to non-current assets other than financial instruments, deferred tax assets, net defined benefit assets and rights arising under insurance contracts. [Refer: Deferred tax assets; Classes of financial instruments [domain]; Non-current assets]" } } }, "auth_ref": [ "r101", "r106" ] }, "tlx_AdjustedEarningsLossBeforeInterestTaxDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "AdjustedEarningsLossBeforeInterestTaxDepreciationAndAmortization", "crdr": "credit", "presentation": [ "http://telixpharma.com/role/SegmentreportingScheduleofReconciliationofSegmentAdjustedEBITDAtoProfitLossBeforeIncomeTaxesDetails", "http://telixpharma.com/role/SegmentreportingScheduleofSegmentPerformanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total segment adjusted EBITDA", "label": "Adjusted Earnings (Loss) Before Interest, Tax, Depreciation And Amortization", "documentation": "The amount of adjusted earnings before interest, tax, depreciation and amortization of the entity." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://telixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "ifrs-full_AmortisationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AmortisationExpense", "crdr": "debit", "calculation": { "http://telixpharma.com/role/ProfitandlossinformationScheduleofDepreciationandamortizationDetails": { "parentTag": "ifrs-full_DepreciationAndAmortisationExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://telixpharma.com/role/ProfitandlossinformationScheduleofDepreciationandamortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of intangible assets", "label": "Amortisation expense" } } }, "auth_ref": [ "r296" ] }, "ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AmortisationIntangibleAssetsOtherThanGoodwill", "presentation": [ "http://telixpharma.com/role/IntangibleassetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Amortization charge", "label": "Amortisation, intangible assets other than goodwill" } } }, "auth_ref": [ "r23", "r156" ] }, "ifrs-full_Assets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Assets", "crdr": "debit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition": { "parentTag": "ifrs-full_NetAssetsLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition", "http://telixpharma.com/role/SegmentreportingScheduleofOperatingSegmentAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "terseLabel": "Total assets", "label": "Assets" } }, "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r55", "r56", "r57", "r100", "r104", "r175", "r176", "r203" ] }, "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AttributionOfExpensesByNatureToTheirFunctionAxis", "presentation": [ "http://telixpharma.com/role/ProfitandlossinformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Attribution of expenses by nature to their function [axis]", "label": "Attribution of expenses by nature to their function [axis]" } } }, "auth_ref": [ "r293", "r296" ] }, "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AttributionOfExpensesByNatureToTheirFunctionDomain", "presentation": [ "http://telixpharma.com/role/ProfitandlossinformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Attribution of expenses by nature to their function [domain]", "label": "Attribution of expenses by nature to their function [domain]" } } }, "auth_ref": [ "r293", "r296" ] }, "country_BE": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2025", "localname": "BE", "presentation": [ "http://telixpharma.com/role/SegmentreportingScheduleofGeographicalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Belgium", "label": "BELGIUM" } } }, "auth_ref": [] }, "ifrs-full_BankAndSimilarCharges": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BankAndSimilarCharges", "crdr": "debit", "calculation": { "http://telixpharma.com/role/ProfitandlossinformationScheduleofFinanceCostsDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://telixpharma.com/role/ProfitandlossinformationScheduleofFinanceCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bank fees", "label": "Bank and similar charges" } } }, "auth_ref": [ "r296" ] }, "ifrs-full_BankBorrowingsUndiscountedCashFlows": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BankBorrowingsUndiscountedCashFlows", "crdr": "credit", "calculation": { "http://telixpharma.com/role/ContractualmaturitiesoffinancialliabilitiesDetails": { "parentTag": "ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://telixpharma.com/role/ContractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings", "label": "Bank borrowings, undiscounted cash flows" } }, "en": { "role": { "documentation": "The amount of contractual undiscounted cash flows in relation to bank borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r256", "r260" ] }, "tlx_BankLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "BankLoansMember", "presentation": [ "http://telixpharma.com/role/BorrowingsScheduleofFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bank loans", "label": "Bank Loans [Member]", "documentation": "The member stands for Bank Loans." } } }, "auth_ref": [] }, "ifrs-full_BasicEarningsLossPerShareFromContinuingOperations": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BasicEarningsLossPerShareFromContinuingOperations", "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome" ], "lang": { "en-us": { "role": { "terseLabel": "Basic earnings/(loss) per share from continuing operations after income tax attributable to the ordinary equity holders of the Company (in dollars per share)", "label": "Basic earnings (loss) per share from continuing operations" } }, "en": { "role": { "documentation": "Basic earnings (loss) per share from continuing operations. [Refer: Basic earnings (loss) per share; Continuing operations, unless line item indicates otherwise [member]]" } } }, "auth_ref": [ "r14", "r15" ] }, "ifrs-full_BondsIssued": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BondsIssued", "crdr": "credit", "presentation": [ "http://telixpharma.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bonds issued", "label": "Bonds issued" } }, "en": { "role": { "documentation": "The amount of bonds issued by the entity." } } }, "auth_ref": [ "r296" ] }, "tlx_BondsRepurchased": { "xbrltype": "monetaryItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "BondsRepurchased", "crdr": "debit", "presentation": [ "http://telixpharma.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repurchase amount", "label": "Bonds Repurchased", "documentation": "Bonds Repurchased" } } }, "auth_ref": [] }, "ifrs-full_BorrowingCostsIncurred": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingCostsIncurred", "presentation": [ "http://telixpharma.com/role/BorrowingsScheduleofConvertibleBondsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Transaction costs", "label": "Borrowing costs incurred" } }, "en": { "role": { "documentation": "The amount of interest and other costs that an entity incurs in connection with the borrowing of funds." } } }, "auth_ref": [ "r296" ] }, "ifrs-full_Borrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Borrowings", "crdr": "credit", "calculation": { "http://telixpharma.com/role/ContractualmaturitiesoffinancialliabilitiesDetails": { "parentTag": "ifrs-full_FinancialLiabilities", "weight": 1.0, "order": 2.0 }, "http://telixpharma.com/role/BorrowingsScheduleofConvertibleBondsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://telixpharma.com/role/BorrowingsScheduleofConvertibleBondsDetails", "http://telixpharma.com/role/ContractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Opening balance", "periodEndLabel": "Closing balance", "totalLabel": "Total borrowings", "netLabel": "Borrowings, carrying amount", "label": "Borrowings" } }, "en": { "role": { "documentation": "The amount of outstanding funds that the entity is obligated to repay." } } }, "auth_ref": [ "r297" ] }, "ifrs-full_BorrowingsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Borrowings [abstract]", "label": "Borrowings [abstract]" } } }, "auth_ref": [] }, "ifrs-full_BorrowingsByNameAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsByNameAxis", "presentation": [ "http://telixpharma.com/role/BorrowingsNarrativeDetails", "http://telixpharma.com/role/BorrowingsScheduleofConvertibleBondsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings by name [axis]", "label": "Borrowings by name [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r289" ] }, "ifrs-full_BorrowingsByNameDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsByNameDomain", "presentation": [ "http://telixpharma.com/role/BorrowingsNarrativeDetails", "http://telixpharma.com/role/BorrowingsScheduleofConvertibleBondsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings by name [domain]", "label": "Borrowings by name [domain]" } }, "en": { "role": { "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]" } } }, "auth_ref": [ "r289" ] }, "ifrs-full_BorrowingsInterestRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsInterestRate", "presentation": [ "http://telixpharma.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Interest rate", "label": "Borrowings, interest rate" } }, "en": { "role": { "documentation": "The interest rate on borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r289" ] }, "ifrs-full_BrandNamesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BrandNamesMember", "presentation": [ "http://telixpharma.com/role/IntangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intellectual property", "label": "Brand names [member]" } }, "en": { "role": { "documentation": "This member stands for a class of intangible assets representing rights to a group of complementary assets such as a trademark (or service mark) and its related trade name, formulas, recipes and technological expertise. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r233" ] }, "ifrs-full_BusinessCombinationsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BusinessCombinationsAxis", "presentation": [ "http://telixpharma.com/role/EquityScheduleofShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business combinations [axis]", "label": "Business combinations [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r79", "r167" ] }, "ifrs-full_BusinessCombinationsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BusinessCombinationsDomain", "presentation": [ "http://telixpharma.com/role/EquityScheduleofShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business combinations [domain]", "label": "Business combinations [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Business combinations' axis if no other member is used." } } }, "auth_ref": [ "r79", "r81", "r167" ] }, "country_CA": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2025", "localname": "CA", "presentation": [ "http://telixpharma.com/role/SegmentreportingScheduleofGeographicalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Canada", "label": "CANADA" } } }, "auth_ref": [] }, "ifrs-full_CapitalCommitments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CapitalCommitments", "crdr": "credit", "presentation": [ "http://telixpharma.com/role/ContingentliabilitiesandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital commitments", "label": "Capital commitments" } }, "en": { "role": { "documentation": "The amount of future capital expenditures that the entity is committed to make." } } }, "auth_ref": [ "r296" ] }, "tlx_CapitalReserveDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "CapitalReserveDeficit", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition" ], "lang": { "en-us": { "role": { "verboseLabel": "Share capital reserve", "label": "Capital Reserve (Deficit)", "documentation": "A component of equity representing the capital reserves(deficit)." } } }, "auth_ref": [] }, "ifrs-full_CapitalReserveMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CapitalReserveMember", "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofchangesinequity" ], "lang": { "en-us": { "role": { "terseLabel": "Share capital reserve", "label": "Capital reserve [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing capital reserves." } } }, "auth_ref": [ "r295" ] }, "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis", "presentation": [ "http://telixpharma.com/role/IntangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]", "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r5", "r6", "r20", "r24", "r27", "r28", "r29", "r30", "r31", "r80", "r88", "r89", "r146", "r147", "r153", "r157", "r160", "r161", "r162", "r163", "r164", "r168", "r171", "r172" ] }, "ifrs-full_CarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CarryingAmountMember", "presentation": [ "http://telixpharma.com/role/IntangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying amount", "label": "Carrying amount [member]" } } }, "auth_ref": [ "r6", "r24", "r27", "r29", "r30", "r80", "r88", "r89", "r147", "r157", "r160", "r162", "r163", "r168", "r171", "r172" ] }, "ifrs-full_CashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashAndCashEquivalents", "crdr": "debit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows", "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition", "http://telixpharma.com/role/MaterialaccountingpolicyinformationDetails", "http://telixpharma.com/role/SegmentreportingNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "periodStartLabel": "Cash and cash equivalents at the beginning of the half-year", "periodEndLabel": "Cash and cash equivalents at the end of the half-year", "label": "Cash and cash equivalents" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } } }, "auth_ref": [ "r38", "r51", "r140", "r198" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by/(used in) financing activities", "label": "Cash flows from (used in) financing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations." } } }, "auth_ref": [ "r32", "r39" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities", "label": "Cash flows from (used in) financing activities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Cash flows from (used in) investing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations." } } }, "auth_ref": [ "r32", "r39" ] }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities", "label": "Cash flows from (used in) investing activities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivities", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows", "http://telixpharma.com/role/MaterialaccountingpolicyinformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash from operating activities", "terseLabel": "Net cash from operating activities", "label": "Cash flows from (used in) operating activities" } } }, "auth_ref": [ "r32", "r39" ] }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities", "label": "Cash flows from (used in) operating activities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments for acquisition of subsidiaries, net of cash acquired", "label": "Cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities" } }, "en": { "role": { "documentation": "The aggregate cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities. [Refer: Total for all subsidiaries [member]]" } } }, "auth_ref": [ "r37" ] }, "ifrs-full_ChangesInEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ChangesInEquity", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofchangesinequity": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://telixpharma.com/role/EquityScheduleofOtherReservesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://telixpharma.com/role/EquityScheduleofOtherReservesDetails", "http://telixpharma.com/role/Interimconsolidatedstatementofchangesinequity" ], "lang": { "en-us": { "role": { "totalLabel": "Total increase (decrease) in equity", "label": "Increase (decrease) in equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity. [Refer: Equity]" } } }, "auth_ref": [ "r191" ] }, "ifrs-full_ChangesInEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ChangesInEquityAbstract", "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofchangesinequity" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in equity [Abstract]", "label": "Changes in equity [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfFinancialLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialLiabilitiesAxis", "presentation": [ "http://telixpharma.com/role/BorrowingsScheduleofFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities arising from financing activities [axis]", "label": "Classes of financial liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r93", "r94", "r114", "r115" ] }, "ifrs-full_ClassesOfFinancialLiabilitiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialLiabilitiesDomain", "presentation": [ "http://telixpharma.com/role/BorrowingsScheduleofFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities arising from financing activities [domain]", "label": "Classes of financial liabilities [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r93", "r94", "r114", "r115" ] }, "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis", "presentation": [ "http://telixpharma.com/role/IntangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of intangible assets other than goodwill [axis]", "label": "Classes of intangible assets other than goodwill [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r25", "r158" ] }, "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillDomain", "presentation": [ "http://telixpharma.com/role/IntangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of intangible assets other than goodwill [domain]", "label": "Classes of intangible assets other than goodwill [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used." } } }, "auth_ref": [ "r25", "r158" ] }, "ifrs-full_ClassesOfShareCapitalAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfShareCapitalAxis", "presentation": [ "http://telixpharma.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of share capital [axis]", "label": "Classes of share capital [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r135", "r179", "r215" ] }, "ifrs-full_ClassesOfShareCapitalDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfShareCapitalDomain", "presentation": [ "http://telixpharma.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of share capital [domain]", "label": "Classes of share capital [domain]" } }, "en": { "role": { "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used." } } }, "auth_ref": [ "r135", "r179", "r215" ] }, "tlx_CommitmentsAndContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "CommitmentsAndContingenciesLineItems", "presentation": [ "http://telixpharma.com/role/ContingentliabilitiesandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies [Line Items]", "label": "Commitments And Contingencies [Line Items]", "documentation": "Line items represent concepts of commitments." } } }, "auth_ref": [] }, "tlx_CommitmentsAndContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "CommitmentsAndContingenciesTable", "presentation": [ "http://telixpharma.com/role/ContingentliabilitiesandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies [Table]", "label": "Commitments And Contingencies [Table]", "documentation": "Commitments and contingencies [Table]" } } }, "auth_ref": [] }, "ifrs-full_ComponentsOfEquityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfEquityAxis", "presentation": [ "http://telixpharma.com/role/EquityNarrativeDetails", "http://telixpharma.com/role/EquityScheduleofOtherReservesDetails", "http://telixpharma.com/role/EquityScheduleofShareCapitalDetails", "http://telixpharma.com/role/Interimconsolidatedstatementofchangesinequity" ], "lang": { "en-us": { "role": { "terseLabel": "Components of equity [axis]", "label": "Components of equity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r192" ] }, "ifrs-full_ComponentsOfEquityDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfEquityDomain", "presentation": [ "http://telixpharma.com/role/EquityNarrativeDetails", "http://telixpharma.com/role/EquityScheduleofOtherReservesDetails", "http://telixpharma.com/role/EquityScheduleofShareCapitalDetails", "http://telixpharma.com/role/Interimconsolidatedstatementofchangesinequity" ], "lang": { "en-us": { "role": { "terseLabel": "Components of equity [domain]", "label": "Components of equity [domain]" } }, "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } } }, "auth_ref": [ "r192" ] }, "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract", "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome" ], "lang": { "en-us": { "role": { "terseLabel": "Items to be reclassified to profit or loss in subsequent periods:", "label": "Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract", "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome" ], "lang": { "en-us": { "role": { "terseLabel": "Items that will not be reclassified to profit or loss in subsequent periods:", "label": "Components of other comprehensive income that will not be reclassified to profit or loss, net of tax [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComprehensiveIncome", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome": { "parentTag": "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent", "weight": 1.0, "order": 1.0 }, "http://telixpharma.com/role/Interimconsolidatedstatementofchangesinequity": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://telixpharma.com/role/EquityScheduleofOtherReservesDetails", "http://telixpharma.com/role/Interimconsolidatedstatementofchangesinequity", "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome" ], "lang": { "en-us": { "role": { "totalLabel": "Total comprehensive income for the period", "label": "Comprehensive income" } }, "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } } }, "auth_ref": [ "r41", "r43", "r48", "r151", "r166", "r187", "r220", "r245" ] }, "ifrs-full_ComprehensiveIncomeAttributableToAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComprehensiveIncomeAttributableToAbstract", "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome" ], "lang": { "en-us": { "role": { "terseLabel": "Total comprehensive income for the period attributable to:", "label": "Comprehensive income attributable to [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComprehensiveIncomeAttributableToOwnersOfParent", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome" ], "lang": { "en-us": { "role": { "totalLabel": "Owners of Telix Pharmaceuticals Limited", "label": "Comprehensive income, attributable to owners of parent" } }, "en": { "role": { "documentation": "The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]" } } }, "auth_ref": [ "r187", "r222" ] }, "tlx_ComprehensiveIncomeFromContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "ComprehensiveIncomeFromContinuingOperationsAbstract", "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome" ], "lang": { "en-us": { "role": { "terseLabel": "Continuing operations", "label": "Comprehensive Income From Continuing Operations [Abstract]", "documentation": "Comprehensive income from continuing operations [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_ComputerSoftwareMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComputerSoftwareMember", "presentation": [ "http://telixpharma.com/role/IntangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Software", "label": "Computer software [member]" } }, "en": { "role": { "documentation": "This member stands for a class of intangible assets representing computer software. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r234" ] }, "tlx_ContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "ContingentConsideration", "crdr": "credit", "calculation": { "http://telixpharma.com/role/ContractualmaturitiesoffinancialliabilitiesDetails": { "parentTag": "ifrs-full_FinancialLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://telixpharma.com/role/ContractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration, carrying amount", "label": "Contingent Consideration", "documentation": "Business acquisition amount of contingent consideration recognized." } } }, "auth_ref": [] }, "tlx_ContingentConsiderationLiabilityUndiscountedCashFlows": { "xbrltype": "monetaryItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "ContingentConsiderationLiabilityUndiscountedCashFlows", "crdr": "credit", "calculation": { "http://telixpharma.com/role/ContractualmaturitiesoffinancialliabilitiesDetails": { "parentTag": "ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://telixpharma.com/role/ContractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration", "label": "Contingent Consideration Liability, Undiscounted Cash Flows", "documentation": "Contingent Consideration Liability, Undiscounted Cash Flows" } } }, "auth_ref": [] }, "ifrs-full_ContractualCapitalCommitments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ContractualCapitalCommitments", "crdr": "credit", "presentation": [ "http://telixpharma.com/role/ContingentliabilitiesandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital commitments", "label": "Contractual capital commitments" } }, "en": { "role": { "documentation": "The amount of capital commitments for which the entity has entered into a contract. [Refer: Capital commitments]" } } }, "auth_ref": [ "r296" ] }, "tlx_ConvertibleBondsMember": { "xbrltype": "domainItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "ConvertibleBondsMember", "presentation": [ "http://telixpharma.com/role/BorrowingsScheduleofConvertibleBondsDetails", "http://telixpharma.com/role/BorrowingsScheduleofFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible bonds", "label": "Convertible Bonds [Member]", "documentation": "This member stands for convertible bonds." } } }, "auth_ref": [] }, "tlx_ConvertibleNoteDue2029ExistingBondsMember": { "xbrltype": "domainItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "ConvertibleNoteDue2029ExistingBondsMember", "presentation": [ "http://telixpharma.com/role/BorrowingsNarrativeDetails", "http://telixpharma.com/role/BorrowingsScheduleofConvertibleBondsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Note Due 2029 (\"Existing Bonds\")", "label": "Convertible Note Due 2029 (\"Existing Bonds\") [Member]", "documentation": "Convertible Note Due 2029 (\"Existing Bonds\")" } } }, "auth_ref": [] }, "tlx_ConvertibleNoteDue2031NewBondsMember": { "xbrltype": "domainItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "ConvertibleNoteDue2031NewBondsMember", "presentation": [ "http://telixpharma.com/role/BorrowingsNarrativeDetails", "http://telixpharma.com/role/BorrowingsScheduleofConvertibleBondsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Note Due 2031 (\"New Bonds\")", "label": "Convertible Note Due 2031 (\"New Bonds\") [Member]", "documentation": "Convertible Note Due 2031 (\"New Bonds\")" } } }, "auth_ref": [] }, "ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember", "presentation": [ "http://telixpharma.com/role/IntangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Patents", "label": "Copyrights, patents and other industrial property rights, service and operating rights [member]" } }, "en": { "role": { "documentation": "This member stands for a class of intangible assets representing copyrights, patents and other industrial property rights, service and operating rights. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r235" ] }, "tlx_CorporateInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "CorporateInformationAbstract", "lang": { "en-us": { "role": { "terseLabel": "Corporate information [Abstract]", "label": "Corporate Information [Abstract]", "documentation": "Corporate information [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_CostOfSales": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CostOfSales", "crdr": "debit", "calculation": { "http://telixpharma.com/role/SegmentreportingScheduleofSegmentPerformanceDetails": { "parentTag": "ifrs-full_GrossProfit", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome", "http://telixpharma.com/role/SegmentreportingScheduleofSegmentPerformanceDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Cost of sales", "label": "Cost of sales" } } }, "auth_ref": [ "r185", "r227" ] }, "ifrs-full_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CostOfSalesMember", "presentation": [ "http://telixpharma.com/role/ProfitandlossinformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of Sales", "label": "Cost of sales [member]" } } }, "auth_ref": [ "r293", "r296" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "ifrs-full_CurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAssets", "crdr": "debit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Current assets" } }, "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } } }, "auth_ref": [ "r44", "r208", "r245" ] }, "ifrs-full_CurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAssetsAbstract", "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Current assets [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CurrentBondsIssuedAndCurrentPortionOfNoncurrentBondsIssued": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentBondsIssuedAndCurrentPortionOfNoncurrentBondsIssued", "crdr": "credit", "calculation": { "http://telixpharma.com/role/BorrowingsScheduleofBorrowingsDetails": { "parentTag": "tlx_UnsecuredBorrowingsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://telixpharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current unsecured convertible bonds", "label": "Current bonds issued and current portion of non-current bonds issued" } }, "en": { "role": { "documentation": "The amount of current bonds issued and the current portion of non-current bonds issued. [Refer: Bonds issued]" } } }, "auth_ref": [ "r296" ] }, "ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowingsByTypeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowingsByTypeAbstract", "presentation": [ "http://telixpharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current", "label": "Current borrowings and current portion of non-current borrowings, by type [abstract]" } } }, "auth_ref": [] }, "tlx_CurrentContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "CurrentContingentConsideration", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration", "label": "Current Contingent Consideration", "documentation": "The amount of current contingent consideration." } } }, "auth_ref": [] }, "ifrs-full_CurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentContractLiabilities", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition" ], "lang": { "en-us": { "role": { "terseLabel": "Contract liabilities", "label": "Current contract liabilities" } }, "en": { "role": { "documentation": "The amount of current contract liabilities. [Refer: Contract liabilities]" } } }, "auth_ref": [ "r59" ] }, "tlx_CurrentEmployeeBenefitObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "CurrentEmployeeBenefitObligations", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition" ], "lang": { "en-us": { "role": { "terseLabel": "Employee benefit obligations", "label": "Current Employee Benefit Obligations", "documentation": "The amount of current employee benefit obligations." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://telixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "ifrs-full_CurrentLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLeaseLiabilities", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities", "label": "Current lease liabilities" } }, "en": { "role": { "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r65" ] }, "ifrs-full_CurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLiabilities", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition": { "parentTag": "ifrs-full_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } } }, "auth_ref": [ "r46", "r209", "r245" ] }, "ifrs-full_CurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLiabilitiesAbstract", "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Current liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CurrentProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentProvisions", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition" ], "lang": { "en-us": { "role": { "verboseLabel": "Provisions", "label": "Current provisions" } }, "en": { "role": { "documentation": "The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]" } } }, "auth_ref": [ "r200" ] }, "ifrs-full_CurrentSecuredBankLoansReceivedAndCurrentPortionOfNoncurrentSecuredBankLoansReceived": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentSecuredBankLoansReceivedAndCurrentPortionOfNoncurrentSecuredBankLoansReceived", "crdr": "credit", "calculation": { "http://telixpharma.com/role/BorrowingsScheduleofBorrowingsDetails": { "parentTag": "tlx_SecuredBorrowingsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://telixpharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current secured bank loans", "label": "Current secured bank loans received and current portion of non-current secured bank loans received" } }, "en": { "role": { "documentation": "The amount of current secured bank loans received and the current portion of non-current secured bank loans received. [Refer: Secured bank loans received]" } } }, "auth_ref": [ "r296" ] }, "ifrs-full_CurrentTaxAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentTaxAssetsCurrent", "crdr": "debit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition" ], "lang": { "en-us": { "role": { "terseLabel": "Current tax asset", "label": "Current tax assets, current" } }, "en": { "role": { "documentation": "The current amount of current tax assets. [Refer: Current tax assets]" } } }, "auth_ref": [ "r201" ] }, "ifrs-full_CurrentTaxLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentTaxLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition" ], "lang": { "en-us": { "role": { "terseLabel": "Current tax payable", "label": "Current tax liabilities, current" } }, "en": { "role": { "documentation": "The current amount of current tax liabilities. [Refer: Current tax liabilities]" } } }, "auth_ref": [ "r201" ] }, "tlx_CustomerRelationshipsAndBrandsMember": { "xbrltype": "domainItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "CustomerRelationshipsAndBrandsMember", "presentation": [ "http://telixpharma.com/role/IntangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer relationships and brands", "label": "Customer Relationships And Brands [Member]", "documentation": "This member stands for a class of intangible assets representing customer relationships and brands." } } }, "auth_ref": [] }, "tlx_DedicaidGmbHMember": { "xbrltype": "domainItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "DedicaidGmbHMember", "presentation": [ "http://telixpharma.com/role/EquityScheduleofShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dedicaid", "label": "Dedicaid GmbH [Member]", "documentation": "The name of the entity which is controlled by another entity." } } }, "auth_ref": [] }, "tlx_DeferredConsiderationIndemnityPeriod": { "xbrltype": "durationItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "DeferredConsiderationIndemnityPeriod", "presentation": [ "http://telixpharma.com/role/EquityScheduleofShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred consideration indemnity period", "label": "Deferred Consideration Indemnity Period", "documentation": "Deferred Consideration Indemnity Period" } } }, "auth_ref": [] }, "ifrs-full_DeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DeferredTaxAssets", "crdr": "debit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets", "label": "Deferred tax assets" } }, "en": { "role": { "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } } }, "auth_ref": [ "r4", "r145", "r202", "r204" ] }, "ifrs-full_DeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liabilities", "label": "Deferred tax liabilities" } }, "en": { "role": { "documentation": "The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]" } } }, "auth_ref": [ "r4", "r145", "r202", "r204" ] }, "ifrs-full_DepreciationAndAmortisationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DepreciationAndAmortisationExpense", "crdr": "debit", "calculation": { "http://telixpharma.com/role/ProfitandlossinformationScheduleofDepreciationandamortizationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://telixpharma.com/role/ProfitandlossinformationScheduleofDepreciationandamortizationDetails", "http://telixpharma.com/role/SegmentreportingScheduleofReconciliationofSegmentAdjustedEBITDAtoProfitLossBeforeIncomeTaxesDetails", "http://telixpharma.com/role/SegmentreportingScheduleofSegmentPerformanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "negatedLabel": "Depreciation and amortization", "totalLabel": "Depreciation and amortization", "label": "Depreciation and amortisation expense" } }, "en": { "role": { "documentation": "The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives." } } }, "auth_ref": [ "r52", "r98", "r106", "r186", "r227", "r270" ] }, "ifrs-full_DepreciationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DepreciationExpense", "crdr": "debit", "calculation": { "http://telixpharma.com/role/ProfitandlossinformationScheduleofDepreciationandamortizationDetails": { "parentTag": "ifrs-full_DepreciationAndAmortisationExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://telixpharma.com/role/ProfitandlossinformationScheduleofDepreciationandamortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation expense" } } }, "auth_ref": [ "r296" ] }, "tlx_DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "DescriptionOfAccountingPolicyForGoingConcernPolicyTextBlock", "presentation": [ "http://telixpharma.com/role/MaterialaccountingpolicyinformationPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Going concern", "label": "Description Of Accounting Policy For Going Concern [Policy Text Block]", "documentation": "The description of the entity's accounting policy for going concern." } } }, "auth_ref": [] }, "tlx_DescriptionOfAccountingPolicyForOtherIncomePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "DescriptionOfAccountingPolicyForOtherIncomePolicyTextBlock", "presentation": [ "http://telixpharma.com/role/MaterialaccountingpolicyinformationPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Other income", "label": "Description Of Accounting Policy For Other Income [Policy Text Block]", "documentation": "Description Of Accounting Policy For Other Income" } } }, "auth_ref": [] }, "ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DilutedEarningsLossPerShareFromContinuingOperations", "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome" ], "lang": { "en-us": { "role": { "verboseLabel": "Diluted earnings/(loss) per share from continuing operations after income tax attributable to the ordinary equity holders of the Company (in dollars per share)", "label": "Diluted earnings (loss) per share from continuing operations" } }, "en": { "role": { "documentation": "Diluted earnings (loss) per share from continuing operations. [Refer: Continuing operations, unless line item indicates otherwise [member]; Diluted earnings (loss) per share]" } } }, "auth_ref": [ "r14", "r15" ] }, "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "presentation": [ "http://telixpharma.com/role/MaterialaccountingpolicyinformationPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of preparation", "label": "Disclosure of basis of preparation of financial statements [text block]" } } }, "auth_ref": [ "r290" ] }, "ifrs-full_DisclosureOfBorrowingsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfBorrowingsExplanatory", "presentation": [ "http://telixpharma.com/role/Borrowings" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings", "label": "Disclosure of borrowings [text block]" } }, "en": { "role": { "documentation": "The disclosure of borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r290" ] }, "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalAbstract", "presentation": [ "http://telixpharma.com/role/EquityScheduleofShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of classes of share capital [abstract]", "label": "Disclosure of classes of share capital [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalExplanatory", "presentation": [ "http://telixpharma.com/role/EquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Classes of Share Capital", "label": "Disclosure of classes of share capital [text block]" } }, "en": { "role": { "documentation": "The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]" } } }, "auth_ref": [ "r135", "r179", "r215" ] }, "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalLineItems", "presentation": [ "http://telixpharma.com/role/EquityNarrativeDetails", "http://telixpharma.com/role/EquityScheduleofOtherReservesDetails", "http://telixpharma.com/role/EquityScheduleofShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of classes of share capital [line items]", "label": "Disclosure of classes of share capital [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalTable", "presentation": [ "http://telixpharma.com/role/EquityNarrativeDetails", "http://telixpharma.com/role/EquityScheduleofOtherReservesDetails", "http://telixpharma.com/role/EquityScheduleofShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of classes of share capital [table]", "label": "Disclosure of classes of share capital [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to classes of share capital." } } }, "auth_ref": [ "r135", "r179", "r215" ] }, "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "presentation": [ "http://telixpharma.com/role/ContingentliabilitiesandCommitments" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent liabilities and Commitments", "label": "Disclosure of commitments and contingent liabilities [text block]" } }, "en": { "role": { "documentation": "The disclosure of commitments and contingent liabilities. [Refer: Classes of contingent liabilities [domain]]" } } }, "auth_ref": [ "r290" ] }, "tlx_DisclosureOfCommitmentsContractualObligationsExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "DisclosureOfCommitmentsContractualObligationsExplanatoryTableTextBlock", "presentation": [ "http://telixpharma.com/role/ContingentliabilitiesandCommitmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Estimated Based on Contractual Obligations", "label": "Disclosure Of Commitments, Contractual Obligations Explanatory [Table Text Block]", "documentation": "The tabular disclosure commitments estimated based on the contractual obligations." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfContingentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfContingentLiabilitiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Disclosure of contingent liabilities [abstract]", "label": "Disclosure of contingent liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "presentation": [ "http://telixpharma.com/role/BorrowingsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Borrowings", "label": "Disclosure of detailed information about borrowings [text block]" } }, "en": { "role": { "documentation": "The disclosure of detailed information about borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r289" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsLineItems", "presentation": [ "http://telixpharma.com/role/BorrowingsNarrativeDetails", "http://telixpharma.com/role/BorrowingsScheduleofConvertibleBondsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about borrowings [line items]", "label": "Disclosure of detailed information about borrowings [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable", "presentation": [ "http://telixpharma.com/role/BorrowingsNarrativeDetails", "http://telixpharma.com/role/BorrowingsScheduleofConvertibleBondsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about borrowings [table]", "label": "Disclosure of detailed information about borrowings [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of borrowings." } } }, "auth_ref": [ "r289" ] }, "tlx_DisclosureOfDetailedInformationAboutConvertibleBondsReportedInStatementOfFinancialPositionTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "DisclosureOfDetailedInformationAboutConvertibleBondsReportedInStatementOfFinancialPositionTableTextBlock", "presentation": [ "http://telixpharma.com/role/BorrowingsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Convertible Bonds", "label": "Disclosure Of Detailed Information About Convertible Bonds Reported In Statement Of Financial Position [Table Text Block]", "documentation": "The disclosure of detailed information about convertible bonds reported in statement of financial position." } } }, "auth_ref": [] }, "tlx_DisclosureOfDetailedInformationAboutEmploymentCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "DisclosureOfDetailedInformationAboutEmploymentCostsTextBlock", "presentation": [ "http://telixpharma.com/role/ProfitandlossinformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Employment Costs", "label": "Disclosure Of Detailed Information About Employment Costs [Text Block]", "documentation": "The disclosure of detailed information about employment costs." } } }, "auth_ref": [] }, "tlx_DisclosureOfDetailedInformationAboutFinanceCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "DisclosureOfDetailedInformationAboutFinanceCostsTextBlock", "presentation": [ "http://telixpharma.com/role/ProfitandlossinformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finance Costs", "label": "Disclosure Of Detailed Information About Finance Costs [Text Block]", "documentation": "The disclosure of detailed information about finance costs." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "presentation": [ "http://telixpharma.com/role/ProfitandlossinformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Revenue from Sale and Transfer of Goods and Services", "label": "Disclosure of disaggregation of revenue from contracts with customers [text block]" } } }, "auth_ref": [ "r61", "r117" ] }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems", "presentation": [ "http://telixpharma.com/role/ProfitandlossinformationNarrativeDetails", "http://telixpharma.com/role/ProfitandlossinformationScheduleofRevenuefromContractswithCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of disaggregation of revenue from contracts with customers [line items]", "label": "Disclosure of disaggregation of revenue from contracts with customers [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable", "presentation": [ "http://telixpharma.com/role/ProfitandlossinformationNarrativeDetails", "http://telixpharma.com/role/ProfitandlossinformationScheduleofRevenuefromContractswithCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of disaggregation of revenue from contracts with customers [table]", "label": "Disclosure of disaggregation of revenue from contracts with customers [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the disaggregation of revenue from contracts with customers." } } }, "auth_ref": [ "r61", "r117" ] }, "ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEntitysReportableSegmentsExplanatory", "presentation": [ "http://telixpharma.com/role/Segmentreporting" ], "lang": { "en-us": { "role": { "terseLabel": "Segment reporting", "label": "Disclosure of entity's operating segments [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for operating segments." } } }, "auth_ref": [ "r113" ] }, "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory", "presentation": [ "http://telixpharma.com/role/Eventsoccurringafterthereportingperiod" ], "lang": { "en-us": { "role": { "terseLabel": "Events occurring after the reporting period", "label": "Disclosure of events after reporting period [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for events after the reporting period." } } }, "auth_ref": [ "r0" ] }, "ifrs-full_DisclosureOfFairValueMeasurementExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFairValueMeasurementExplanatory", "presentation": [ "http://telixpharma.com/role/Fairvalue" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value", "label": "Disclosure of fair value measurement [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for fair value measurement." } } }, "auth_ref": [ "r58" ] }, "tlx_DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "DisclosureOfFairValueMeasurementOfAssetsAndLiabilitiesLineItems", "presentation": [ "http://telixpharma.com/role/FairvalueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Fair Value Measurement of Assets and Liabilities [Line Items]", "label": "Disclosure of Fair Value Measurement of Assets and Liabilities [Line Items]", "documentation": "Disclosure of Fair Value Measurement of Assets and Liabilities" } } }, "auth_ref": [] }, "tlx_DisclosureOfFairValueOfAssetsAndLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "DisclosureOfFairValueOfAssetsAndLiabilitiesTable", "presentation": [ "http://telixpharma.com/role/FairvalueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Fair Value of Assets and Liabilities [Table]", "label": "Disclosure of Fair Value of Assets and Liabilities [Table]", "documentation": "Disclosure of fair value of assets and liabilities [table]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialLiabilitiesExplanatory", "presentation": [ "http://telixpharma.com/role/BorrowingsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value Hierarchy", "label": "Disclosure of financial liabilities [text block]" } }, "en": { "role": { "documentation": "The disclosure of financial liabilities. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r95", "r169" ] }, "ifrs-full_DisclosureOfFinancialRiskManagementExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialRiskManagementExplanatory", "presentation": [ "http://telixpharma.com/role/Contractualmaturitiesoffinancialliabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Contractual maturities of financial liabilities", "label": "Disclosure of financial risk management [text block]" } }, "en": { "role": { "documentation": "The disclosure of the entity's financial risk management practices and policies." } } }, "auth_ref": [ "r290" ] }, "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "presentation": [ "http://telixpharma.com/role/Corporateinformation" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate Information", "label": "Disclosure of general information about financial statements [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for general information about financial statements." } } }, "auth_ref": [ "r131", "r194" ] }, "ifrs-full_DisclosureOfGeographicalAreasExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfGeographicalAreasExplanatory", "presentation": [ "http://telixpharma.com/role/SegmentreportingTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Geographical Information", "label": "Disclosure of geographical areas [text block]" } }, "en": { "role": { "documentation": "The disclosure of geographical information." } } }, "auth_ref": [ "r111" ] }, "ifrs-full_DisclosureOfIntangibleAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about intangible assets [abstract]", "label": "Disclosure of detailed information about intangible assets [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsAndGoodwillExplanatory", "presentation": [ "http://telixpharma.com/role/Intangibleassets" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "label": "Disclosure of intangible assets and goodwill [text block]" } }, "en": { "role": { "documentation": "The disclosure of intangible assets and goodwill. [Refer: Intangible assets and goodwill]" } } }, "auth_ref": [ "r290" ] }, "ifrs-full_DisclosureOfIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsLineItems", "presentation": [ "http://telixpharma.com/role/IntangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about intangible assets [line items]", "label": "Disclosure of detailed information about intangible assets [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsTable", "presentation": [ "http://telixpharma.com/role/IntangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about intangible assets [table]", "label": "Disclosure of detailed information about intangible assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of intangible assets." } } }, "auth_ref": [ "r25", "r158" ] }, "ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfMaterialAccountingPolicyInformationExplanatory", "presentation": [ "http://telixpharma.com/role/Materialaccountingpolicyinformation" ], "lang": { "en-us": { "role": { "terseLabel": "Material accounting policy information", "label": "Disclosure of material accounting policy information [text block]" } }, "en": { "role": { "documentation": "The entire disclosure of material accounting policy information applied by the entity." } } }, "auth_ref": [ "r141", "r182", "r193" ] }, "ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract", "presentation": [ "http://telixpharma.com/role/ContractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of maturity analysis for non-derivative financial liabilities [abstract]", "label": "Disclosure of maturity analysis for non-derivative financial liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems", "presentation": [ "http://telixpharma.com/role/ContractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of maturity analysis for non-derivative financial liabilities [line items]", "label": "Disclosure of maturity analysis for non-derivative financial liabilities [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable", "presentation": [ "http://telixpharma.com/role/ContractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of maturity analysis for non-derivative financial liabilities [table]", "label": "Disclosure of maturity analysis for non-derivative financial liabilities [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the maturity analysis for non-derivative financial liabilities." } } }, "auth_ref": [ "r91", "r174" ] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract", "lang": { "en-us": { "role": { "terseLabel": "Disclosure of non-adjusting events after reporting period [abstract]", "label": "Disclosure of non-adjusting events after reporting period [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOperatingSegmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOperatingSegmentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Disclosure of operating segments [abstract]", "label": "Disclosure of operating segments [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOperatingSegmentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOperatingSegmentsExplanatory", "presentation": [ "http://telixpharma.com/role/SegmentreportingTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Operating Segment Assets and Liabilities", "label": "Disclosure of operating segments [text block]" } }, "en": { "role": { "documentation": "The disclosure of operating segments. [Refer: Operating segments [member]]" } } }, "auth_ref": [ "r100" ] }, "ifrs-full_DisclosureOfOperatingSegmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOperatingSegmentsLineItems", "presentation": [ "http://telixpharma.com/role/SegmentreportingNarrativeDetails", "http://telixpharma.com/role/SegmentreportingScheduleofGeographicalInformationDetails", "http://telixpharma.com/role/SegmentreportingScheduleofOperatingSegmentAssetsandLiabilitiesDetails", "http://telixpharma.com/role/SegmentreportingScheduleofReconciliationofSegmentAdjustedEBITDAtoProfitLossBeforeIncomeTaxesDetails", "http://telixpharma.com/role/SegmentreportingScheduleofSegmentPerformanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of operating segments [line items]", "label": "Disclosure of operating segments [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOperatingSegmentsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOperatingSegmentsTable", "presentation": [ "http://telixpharma.com/role/SegmentreportingNarrativeDetails", "http://telixpharma.com/role/SegmentreportingScheduleofGeographicalInformationDetails", "http://telixpharma.com/role/SegmentreportingScheduleofOperatingSegmentAssetsandLiabilitiesDetails", "http://telixpharma.com/role/SegmentreportingScheduleofReconciliationofSegmentAdjustedEBITDAtoProfitLossBeforeIncomeTaxesDetails", "http://telixpharma.com/role/SegmentreportingScheduleofSegmentPerformanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of operating segments [table]", "label": "Disclosure of operating segments [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to operating segments." } } }, "auth_ref": [ "r100" ] }, "tlx_DisclosureOfOtherIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "DisclosureOfOtherIncomeTextBlock", "presentation": [ "http://telixpharma.com/role/ProfitandlossinformationTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Other Income", "label": "Disclosure Of Other Income [Text Block]", "documentation": "The tabular disclosure of other (losses) gains net." } } }, "auth_ref": [] }, "tlx_DisclosureOfProfitAndLossInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "DisclosureOfProfitAndLossInformationTextBlock", "presentation": [ "http://telixpharma.com/role/Profitandlossinformation" ], "lang": { "en-us": { "role": { "terseLabel": "Profit and loss information", "label": "Disclosure Of Profit And Loss Information [Text Block]", "documentation": "Disclosure Of Profit And Loss Information" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory", "presentation": [ "http://telixpharma.com/role/IntangibleassetsTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Intangible Assets", "label": "Disclosure of reconciliation of changes in intangible assets and goodwill [text block]" } }, "en": { "role": { "documentation": "The disclosure of the reconciliation of changes in intangible assets and goodwill. [Refer: Intangible assets and goodwill]" } } }, "auth_ref": [ "r283" ] }, "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems", "presentation": [ "http://telixpharma.com/role/BorrowingsScheduleofFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of reconciliation of liabilities arising from financing activities [line items]", "label": "Disclosure of reconciliation of liabilities arising from financing activities [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable", "presentation": [ "http://telixpharma.com/role/BorrowingsScheduleofFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of reconciliation of liabilities arising from financing activities [table]", "label": "Disclosure of reconciliation of liabilities arising from financing activities [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the reconciliation of liabilities arising from financing activities." } } }, "auth_ref": [ "r139", "r243" ] }, "ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfReservesAndOtherEquityInterestExplanatory", "presentation": [ "http://telixpharma.com/role/EquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Reserves and Share Capital Reserve", "label": "Disclosure of reserves within equity [text block]" } }, "en": { "role": { "documentation": "The disclosure of reserves within equity. [Refer: Other reserves [member]]" } } }, "auth_ref": [ "r136", "r180", "r216" ] }, "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "presentation": [ "http://telixpharma.com/role/Equity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity", "label": "Disclosure of share capital, reserves and other equity interest [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for share capital, reserves and other equity interest." } } }, "auth_ref": [ "r137", "r181", "r217" ] }, "tlx_DiscountRateRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "DiscountRateRiskMember", "presentation": [ "http://telixpharma.com/role/FairvalueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount rate risk", "label": "Discount Rate Risk [Member]", "documentation": "Discount Rate Risk" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://telixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://telixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ifrs-full_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EarningsPerShareAbstract", "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings per share [abstract]", "label": "Earnings per share [abstract]" } } }, "auth_ref": [] }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "crdr": "debit", "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows" ], "lang": { "en-us": { "role": { "terseLabel": "Net foreign exchange differences", "label": "Effect of exchange rate changes on cash and cash equivalents" } }, "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r33", "r34" ] }, "ifrs-full_EliminationOfIntersegmentAmountsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EliminationOfIntersegmentAmountsMember", "presentation": [ "http://telixpharma.com/role/SegmentreportingScheduleofSegmentPerformanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inter-segment eliminations", "label": "Elimination of intersegment amounts [member]" } }, "en": { "role": { "documentation": "This member stands for the elimination of intersegment amounts in the reconciliations of total segment amounts to amounts recognised in the entity's financial statements." } } }, "auth_ref": [ "r264", "r265" ] }, "ifrs-full_EmployeeBenefitsExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EmployeeBenefitsExpense", "crdr": "debit", "calculation": { "http://telixpharma.com/role/ProfitandlossinformationScheduleofEmploymentCostsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://telixpharma.com/role/ProfitandlossinformationScheduleofEmploymentCostsDetails", "http://telixpharma.com/role/SegmentreportingNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unallocated employment costs", "totalLabel": "Total employment costs", "label": "Employee benefits expense" } } }, "auth_ref": [ "r132", "r186", "r227", "r270" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine1", "presentation": [ "http://telixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCityOrTown", "presentation": [ "http://telixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCountry", "presentation": [ "http://telixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Country", "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://telixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://telixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://telixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r276" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFileNumber", "presentation": [ "http://telixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://telixpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r276" ] }, "ifrs-full_Equity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Equity", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://telixpharma.com/role/EquityScheduleofOtherReservesDetails", "http://telixpharma.com/role/Interimconsolidatedstatementofchangesinequity", "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition" ], "lang": { "en-us": { "role": { "totalLabel": "Total equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity" } }, "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } } }, "auth_ref": [ "r40", "r42", "r55", "r56", "r57", "r150", "r165", "r175", "r176", "r184", "r203", "r212" ] }, "ifrs-full_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAbstract", "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition" ], "lang": { "en-us": { "role": { "terseLabel": "Equity", "label": "Equity [abstract]" } } }, "auth_ref": [] }, "ifrs-full_EquityPriceRiskMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityPriceRiskMember", "presentation": [ "http://telixpharma.com/role/FairvalueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity price risk", "label": "Equity price risk [member]" } }, "en": { "role": { "documentation": "This member stands for a component of other price risk that represents the type of risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in equity prices. [Refer: Classes of financial instruments [domain]]" } } }, "auth_ref": [ "r252", "r261" ] }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees", "crdr": "debit", "calculation": { "http://telixpharma.com/role/ProfitandlossinformationScheduleofEmploymentCostsDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://telixpharma.com/role/ProfitandlossinformationScheduleofEmploymentCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payment charge", "label": "Expense from share-based payment transactions with employees" } } }, "auth_ref": [ "r296" ] }, "tlx_FairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "FairValueAbstract", "lang": { "en-us": { "role": { "label": "Fair value [Abstract]", "documentation": "Fair value [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_FinanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceCosts", "crdr": "debit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": -1.0, "order": 3.0 }, "http://telixpharma.com/role/ProfitandlossinformationScheduleofFinanceCostsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome", "http://telixpharma.com/role/ProfitandlossinformationScheduleofFinanceCostsDetails", "http://telixpharma.com/role/SegmentreportingScheduleofReconciliationofSegmentAdjustedEBITDAtoProfitLossBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Finance costs", "negatedTerseLabel": "Finance costs", "totalLabel": "Finance costs", "label": "Finance costs" } } }, "auth_ref": [ "r224" ] }, "ifrs-full_FinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceIncome", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome", "http://telixpharma.com/role/SegmentreportingScheduleofReconciliationofSegmentAdjustedEBITDAtoProfitLossBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance income", "label": "Finance income" } } }, "auth_ref": [ "r299" ] }, "ifrs-full_FinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialLiabilities", "crdr": "credit", "calculation": { "http://telixpharma.com/role/ContractualmaturitiesoffinancialliabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://telixpharma.com/role/BorrowingsScheduleofFairValueHierarchyDetails", "http://telixpharma.com/role/ContractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying amount", "totalLabel": "Total financial liabilities, carrying amount", "label": "Financial liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Classes of financial instruments [domain]; Financial assets; Derivatives [member]]" } } }, "auth_ref": [ "r85" ] }, "ifrs-full_FinancialLiabilitiesAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialLiabilitiesAtFairValue", "crdr": "credit", "presentation": [ "http://telixpharma.com/role/BorrowingsScheduleofFairValueHierarchyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value", "label": "Financial liabilities, at fair value" } }, "en": { "role": { "documentation": "The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]" } } }, "auth_ref": [ "r85" ] }, "ifrs-full_ForeignCountriesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ForeignCountriesMember", "presentation": [ "http://telixpharma.com/role/SegmentreportingScheduleofGeographicalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other countries", "label": "Foreign countries [member]" } }, "en": { "role": { "documentation": "This member stands for countries outside the entity's country of domicile. [Refer: Country of domicile [member]]" } } }, "auth_ref": [ "r109", "r110" ] }, "country_GB": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2025", "localname": "GB", "presentation": [ "http://telixpharma.com/role/SegmentreportingScheduleofGeographicalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "United Kingdom", "label": "UNITED KINGDOM" } } }, "auth_ref": [] }, "tlx_GainLossOnRepurchaseOfConvertibleBonds": { "xbrltype": "monetaryItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "GainLossOnRepurchaseOfConvertibleBonds", "crdr": "credit", "calculation": { "http://telixpharma.com/role/ProfitandlossinformationScheduleofFinanceCostsDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://telixpharma.com/role/ProfitandlossinformationNarrativeDetails", "http://telixpharma.com/role/ProfitandlossinformationScheduleofFinanceCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) on repurchase of convertible bonds", "negatedTerseLabel": "(Gain) on repurchase of convertible bond", "label": "Gain (Loss) On Repurchase Of Convertible Bonds", "documentation": "Gain (Loss) On Repurchase Of Convertible Bonds" } } }, "auth_ref": [] }, "ifrs-full_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome", "http://telixpharma.com/role/SegmentreportingScheduleofReconciliationofSegmentAdjustedEBITDAtoProfitLossBeforeIncomeTaxesDetails", "http://telixpharma.com/role/SegmentreportingScheduleofSegmentPerformanceDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "General and administration costs", "label": "General and administrative expense" } } }, "auth_ref": [ "r296" ] }, "ifrs-full_GeographicalAreasAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GeographicalAreasAxis", "presentation": [ "http://telixpharma.com/role/SegmentreportingScheduleofGeographicalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical areas [axis]", "label": "Geographical areas [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r111", "r228", "r246", "r249", "r266" ] }, "ifrs-full_GeographicalAreasDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GeographicalAreasDomain", "presentation": [ "http://telixpharma.com/role/SegmentreportingScheduleofGeographicalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical areas [domain]", "label": "Geographical areas [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used." } } }, "auth_ref": [ "r111", "r228", "r246", "r249", "r266" ] }, "ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GoodsOrServicesTransferredAtPointInTimeMember", "presentation": [ "http://telixpharma.com/role/ProfitandlossinformationScheduleofRevenuefromContractswithCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "At a point in time", "label": "Goods or services transferred at point in time [member]" } }, "en": { "role": { "documentation": "This member stands for goods or services transferred to customers at a point in time. [Refer: Performance obligations satisfied at point in time [member]]" } } }, "auth_ref": [ "r247", "r267" ] }, "ifrs-full_GoodsOrServicesTransferredOverTimeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GoodsOrServicesTransferredOverTimeMember", "presentation": [ "http://telixpharma.com/role/ProfitandlossinformationScheduleofRevenuefromContractswithCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Over time", "label": "Goods or services transferred over time [member]" } }, "en": { "role": { "documentation": "This member stands for goods or services transferred to customers over time. [Refer: Performance obligations satisfied over time [member]]" } } }, "auth_ref": [ "r247", "r267" ] }, "ifrs-full_GoodwillMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GoodwillMember", "presentation": [ "http://telixpharma.com/role/IntangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill [member]" } }, "en": { "role": { "documentation": "This member stands for goodwill. [Refer: Goodwill]" } } }, "auth_ref": [ "r232", "r268" ] }, "tlx_GovernmentGrantLiabilityUndiscountedCashFlows": { "xbrltype": "monetaryItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "GovernmentGrantLiabilityUndiscountedCashFlows", "crdr": "credit", "calculation": { "http://telixpharma.com/role/ContractualmaturitiesoffinancialliabilitiesDetails": { "parentTag": "ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://telixpharma.com/role/ContractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government grant liability", "label": "Government Grant Liability, Undiscounted Cash Flows", "documentation": "Government Grant Liability, Undiscounted Cash Flows" } } }, "auth_ref": [] }, "ifrs-full_GovernmentGrants": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GovernmentGrants", "crdr": "credit", "calculation": { "http://telixpharma.com/role/ContractualmaturitiesoffinancialliabilitiesDetails": { "parentTag": "ifrs-full_FinancialLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://telixpharma.com/role/ContractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government grant liability, carrying amount", "label": "Government grants" } }, "en": { "role": { "documentation": "The amount of assistance by government in the form of transfers of resources to an entity in return for past or future compliance with certain conditions relating to the operating activities of the entity, recognised as deferred income. They exclude those forms of government assistance that cannot reasonably have a value placed upon them and transactions with government that cannot be distinguished from the normal trading transactions of the entity. [Refer: Deferred income other than contract liabilities; Government [member]]" } } }, "auth_ref": [ "r297" ] }, "ifrs-full_GrossCarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GrossCarryingAmountMember", "presentation": [ "http://telixpharma.com/role/IntangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost", "label": "Gross carrying amount [member]" } } }, "auth_ref": [ "r5", "r20", "r28", "r31", "r80", "r89", "r90", "r146", "r153", "r161", "r164", "r172", "r173", "r251" ] }, "ifrs-full_GrossLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GrossLeaseLiabilities", "crdr": "credit", "calculation": { "http://telixpharma.com/role/ContractualmaturitiesoffinancialliabilitiesDetails": { "parentTag": "ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://telixpharma.com/role/ContractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities", "label": "Gross lease liabilities" } }, "en": { "role": { "documentation": "The amount of contractual undiscounted cash flows in relation to lease liabilities before deducting finance charges. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r68", "r122", "r255" ] }, "ifrs-full_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://telixpharma.com/role/SegmentreportingScheduleofSegmentPerformanceDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome", "http://telixpharma.com/role/SegmentreportingScheduleofSegmentPerformanceDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross profit" } } }, "auth_ref": [ "r271" ] }, "tlx_ImaginAbIncMember": { "xbrltype": "domainItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "ImaginAbIncMember", "presentation": [ "http://telixpharma.com/role/EquityScheduleofShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ImaginAb", "label": "ImaginAb Inc [Member]", "documentation": "ImaginAb Inc" } } }, "auth_ref": [] }, "ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill", "presentation": [ "http://telixpharma.com/role/IntangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairments", "label": "Impairment loss recognised in profit or loss, intangible assets other than goodwill" } } }, "auth_ref": [ "r22", "r155" ] }, "ifrs-full_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Profit or loss [abstract]", "label": "Profit or loss [abstract]" } } }, "auth_ref": [] }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeTaxExpenseContinuingOperations", "crdr": "debit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome": { "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome" ], "lang": { "en-us": { "role": { "negatedLabel": "Income tax benefit", "label": "Tax expense (income)" } } }, "auth_ref": [ "r1", "r2", "r3", "r13", "r54", "r99", "r142", "r143", "r144", "r225" ] }, "ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeTaxesPaidRefundClassifiedAsOperatingActivities", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows" ], "lang": { "en-us": { "role": { "negatedLabel": "Income taxes paid", "label": "Income taxes paid (refund), classified as operating activities" } }, "en": { "role": { "documentation": "The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]" } } }, "auth_ref": [ "r36", "r237" ] }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "crdr": "debit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase/(decrease) in cash held", "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes" } }, "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } } }, "auth_ref": [ "r38", "r140" ] }, "tlx_IncreaseDecreaseInForeignExchangeDifferencesInConvertibleBonds": { "xbrltype": "monetaryItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "IncreaseDecreaseInForeignExchangeDifferencesInConvertibleBonds", "crdr": "debit", "presentation": [ "http://telixpharma.com/role/BorrowingsScheduleofConvertibleBondsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange differences", "label": "Increase (Decrease) In Foreign Exchange Differences In Convertible Bonds", "documentation": "Increase (Decrease) In Foreign Exchange Differences In Convertible Bonds" } } }, "auth_ref": [] }, "tlx_IncreaseDecreaseInNumberOfSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "IncreaseDecreaseInNumberOfSharesIssued", "presentation": [ "http://telixpharma.com/role/EquityScheduleofShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued (in shares)", "label": "Increase (Decrease) In Number Of Shares Issued", "documentation": "The increase (decrease) in the number of shares issued." } } }, "auth_ref": [] }, "tlx_IncreaseDecreaseSharesIssuedThroughExerciseOfShareOptionsAndWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "IncreaseDecreaseSharesIssuedThroughExerciseOfShareOptionsAndWarrants", "presentation": [ "http://telixpharma.com/role/EquityScheduleofShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued through the exercise of share options and warrants (in shares)", "label": "Increase (Decrease) Shares Issued Through Exercise Of Share Options And Warrants", "documentation": "Shares issued as a result of the exercise of stock options and warrants." } } }, "auth_ref": [] }, "tlx_IncreaseDecreaseThroughChangesInProvisionsIntangibleAssetsAndGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "IncreaseDecreaseThroughChangesInProvisionsIntangibleAssetsAndGoodwill", "crdr": "debit", "presentation": [ "http://telixpharma.com/role/IntangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in provisions", "label": "Increase (Decrease) Through Changes in Provisions, Intangible Assets And Goodwill", "documentation": "The increase (decrease) in intangible assets other than goodwill resulting from changes in provision." } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughExerciseOfOptions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughExerciseOfOptions", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofchangesinequity": { "parentTag": "ifrs-full_ChangesInEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofchangesinequity" ], "lang": { "en-us": { "role": { "terseLabel": "Issue of shares on exercise of options", "label": "Increase (decrease) through exercise of options, equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the exercise of options." } } }, "auth_ref": [ "r294" ] }, "tlx_IncreaseDecreaseThroughMeasurementPeriodAdjustmentsIntangibleAssetsAndGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "IncreaseDecreaseThroughMeasurementPeriodAdjustmentsIntangibleAssetsAndGoodwill", "crdr": "debit", "presentation": [ "http://telixpharma.com/role/IntangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement period adjustments", "label": "Increase (Decrease) Through Measurement Period Adjustments, Intangible Assets And Goodwill", "documentation": "Increase (Decrease) Through Measurement Period Adjustments, Intangible Assets And Goodwill" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill", "crdr": "debit", "presentation": [ "http://telixpharma.com/role/IntangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange differences", "label": "Increase (decrease) through net exchange differences, intangible assets and goodwill" } }, "en": { "role": { "documentation": "The increase (decrease) in intangible assets and goodwill resulting from the net exchange differences arising when the financial statements are translated from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets and goodwill]" } } }, "auth_ref": [ "r281" ] }, "tlx_IncreaseDecreaseThroughShareBasedPaymentTransactionsAssociatedWithAcquisitionsEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "IncreaseDecreaseThroughShareBasedPaymentTransactionsAssociatedWithAcquisitionsEquity", "crdr": "credit", "calculation": { "http://telixpharma.com/role/EquityScheduleofOtherReservesDetails": { "parentTag": "ifrs-full_ChangesInEquity", "weight": 1.0, "order": 2.0 }, "http://telixpharma.com/role/Interimconsolidatedstatementofchangesinequity": { "parentTag": "ifrs-full_ChangesInEquity", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://telixpharma.com/role/EquityScheduleofOtherReservesDetails", "http://telixpharma.com/role/Interimconsolidatedstatementofchangesinequity" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payments associated with acquisitions", "label": "Increase (Decrease) Through Share-Based Payment Transactions Associated With Acquisitions, Equity", "documentation": "The increase (decrease) in equity resulting from share-based payment transactions associated with acquisitions." } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "crdr": "credit", "calculation": { "http://telixpharma.com/role/EquityScheduleofOtherReservesDetails": { "parentTag": "ifrs-full_ChangesInEquity", "weight": 1.0, "order": 1.0 }, "http://telixpharma.com/role/Interimconsolidatedstatementofchangesinequity": { "parentTag": "ifrs-full_ChangesInEquity", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://telixpharma.com/role/EquityScheduleofOtherReservesDetails", "http://telixpharma.com/role/Interimconsolidatedstatementofchangesinequity" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payments to employees", "label": "Increase (decrease) through share-based payment transactions, equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } } }, "auth_ref": [ "r190" ] }, "tlx_IncreaseDecreaseThroughTransactionCostsArisingOnConvertibleBondsIssue": { "xbrltype": "monetaryItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "IncreaseDecreaseThroughTransactionCostsArisingOnConvertibleBondsIssue", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofchangesinequity": { "parentTag": "ifrs-full_ChangesInEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofchangesinequity" ], "lang": { "en-us": { "role": { "terseLabel": "Transaction costs arising on convertible bonds issue", "label": "Increase (Decrease) Through Transaction Costs Arising On Convertible Bonds Issue", "documentation": "The increase (decrease) in equity resulting from the transaction costs arising on Convertible Bonds Issue." } } }, "auth_ref": [] }, "tlx_IncreaseDecreaseThroughTransferOnExerciseOfOptionsEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "IncreaseDecreaseThroughTransferOnExerciseOfOptionsEquity", "crdr": "credit", "calculation": { "http://telixpharma.com/role/EquityScheduleofOtherReservesDetails": { "parentTag": "ifrs-full_ChangesInEquity", "weight": 1.0, "order": 4.0 }, "http://telixpharma.com/role/Interimconsolidatedstatementofchangesinequity": { "parentTag": "ifrs-full_ChangesInEquity", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://telixpharma.com/role/EquityScheduleofOtherReservesDetails", "http://telixpharma.com/role/Interimconsolidatedstatementofchangesinequity" ], "lang": { "en-us": { "role": { "terseLabel": "Transfer on exercise of options", "label": "Increase (Decrease) Through Transfer On Exercise Of Options, Equity", "documentation": "The increase (decrease) in equity resulting from the transfer on exercise of options." } } }, "auth_ref": [] }, "tlx_IncreaseDecreaseThroughTransferOnSatisfactionOfAcquisitionPerformanceRights": { "xbrltype": "monetaryItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "IncreaseDecreaseThroughTransferOnSatisfactionOfAcquisitionPerformanceRights", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofchangesinequity": { "parentTag": "ifrs-full_ChangesInEquity", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofchangesinequity" ], "lang": { "en-us": { "role": { "terseLabel": "Transfer on satisfaction of acquisition performance rights", "label": "Increase (Decrease) Through Transfer On Satisfaction Of Acquisition Performance Rights", "documentation": "Increase (Decrease) Through Transfer On Satisfaction Of Acquisition Performance Rights" } } }, "auth_ref": [] }, "tlx_IncreaseDecreaseThroughTransferOnSatisfactionOfAcquisitionPerformanceRightsEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "IncreaseDecreaseThroughTransferOnSatisfactionOfAcquisitionPerformanceRightsEquity", "crdr": "credit", "calculation": { "http://telixpharma.com/role/EquityScheduleofOtherReservesDetails": { "parentTag": "ifrs-full_ChangesInEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://telixpharma.com/role/EquityScheduleofOtherReservesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transfer on satisfaction of acquisition performance rights", "label": "Increase (Decrease) Through Transfer On Satisfaction Of Acquisition Performance Rights, Equity", "documentation": "Increase (Decrease) Through Transfer On Satisfaction Of Acquisition Performance Rights, Equity" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill", "crdr": "debit", "presentation": [ "http://telixpharma.com/role/IntangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassifications", "label": "Increase (decrease) through transfers, intangible assets and goodwill" } }, "en": { "role": { "documentation": "The increase (decrease) in intangible assets and goodwill resulting from transfers. [Refer: Intangible assets and goodwill]" } } }, "auth_ref": [ "r282" ] }, "ifrs-full_IntangibleAssetsAndGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IntangibleAssetsAndGoodwill", "crdr": "debit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://telixpharma.com/role/IntangibleassetsDetails", "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Intangible assets and goodwill" } }, "en": { "role": { "documentation": "The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]" } } }, "auth_ref": [ "r297" ] }, "tlx_InterSegmentRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "InterSegmentRevenue", "crdr": "credit", "calculation": { "http://telixpharma.com/role/SegmentreportingScheduleofSegmentPerformanceDetails": { "parentTag": "ifrs-full_GrossProfit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://telixpharma.com/role/SegmentreportingScheduleofSegmentPerformanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inter-segment revenue", "label": "Inter Segment Revenue", "documentation": "Inter Segment Revenue" } } }, "auth_ref": [] }, "ifrs-full_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://telixpharma.com/role/ProfitandlossinformationScheduleofFinanceCostsDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://telixpharma.com/role/ProfitandlossinformationScheduleofFinanceCostsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Interest expense", "label": "Interest expense" } }, "en": { "role": { "documentation": "The amount of expense arising from interest." } } }, "auth_ref": [ "r53", "r97", "r106" ] }, "ifrs-full_InterestExpenseOnBonds": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestExpenseOnBonds", "crdr": "debit", "calculation": { "http://telixpharma.com/role/ProfitandlossinformationScheduleofFinanceCostsDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://telixpharma.com/role/BorrowingsScheduleofConvertibleBondsDetails", "http://telixpharma.com/role/ProfitandlossinformationScheduleofFinanceCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible bond interest expense", "verboseLabel": "Interest expense", "label": "Interest expense on bonds" } } }, "auth_ref": [ "r296" ] }, "ifrs-full_InterestExpenseOnLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestExpenseOnLeaseLiabilities", "crdr": "debit", "calculation": { "http://telixpharma.com/role/ProfitandlossinformationScheduleofFinanceCostsDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://telixpharma.com/role/ProfitandlossinformationScheduleofFinanceCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense on lease liabilities", "label": "Interest expense on lease liabilities" } } }, "auth_ref": [ "r66", "r120" ] }, "ifrs-full_InterestPaidClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestPaidClassifiedAsOperatingActivities", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest paid", "label": "Interest paid, classified as operating activities" } }, "en": { "role": { "documentation": "The cash outflow for interest paid, classified as operating activities." } } }, "auth_ref": [ "r35" ] }, "tlx_InterestPaidOnConvertibleBonds": { "xbrltype": "monetaryItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "InterestPaidOnConvertibleBonds", "crdr": "credit", "presentation": [ "http://telixpharma.com/role/BorrowingsScheduleofConvertibleBondsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest paid", "label": "Interest Paid On Convertible Bonds", "documentation": "The cash outflow for interest paid on convertible debt, classified as operating activities." } } }, "auth_ref": [] }, "ifrs-full_InterestReceivedClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestReceivedClassifiedAsOperatingActivities", "crdr": "debit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows" ], "lang": { "en-us": { "role": { "terseLabel": "Interest received", "label": "Interest received, classified as operating activities" } }, "en": { "role": { "documentation": "The cash inflow from interest received, classified as operating activities." } } }, "auth_ref": [ "r35" ] }, "ifrs-full_Inventories": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Inventories", "crdr": "debit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Current inventories" } }, "en": { "role": { "documentation": "The amount of current inventories. [Refer: Inventories]" } } }, "auth_ref": [ "r9", "r138", "r196", "r273" ] }, "ifrs-full_IssueOfConvertibleInstruments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssueOfConvertibleInstruments", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofchangesinequity": { "parentTag": "ifrs-full_ChangesInEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofchangesinequity" ], "lang": { "en-us": { "role": { "terseLabel": "Issue of convertible bonds", "label": "Issue of convertible instruments" } }, "en": { "role": { "documentation": "The change in equity resulting from the issuing of convertible instruments." } } }, "auth_ref": [ "r294" ] }, "ifrs-full_IssueOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssueOfEquity", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofchangesinequity": { "parentTag": "ifrs-full_ChangesInEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://telixpharma.com/role/EquityScheduleofShareCapitalDetails", "http://telixpharma.com/role/Interimconsolidatedstatementofchangesinequity" ], "lang": { "en-us": { "role": { "terseLabel": "Issue of shares on acquisitions", "verboseLabel": "Shares issued", "label": "Issue of equity" } }, "en": { "role": { "documentation": "The increase in equity through the issue of equity instruments." } } }, "auth_ref": [ "r190" ] }, "ifrs-full_IssuedCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssuedCapital", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://telixpharma.com/role/EquityScheduleofShareCapitalDetails", "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition" ], "lang": { "en-us": { "role": { "terseLabel": "Share capital", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Issued capital" } }, "en": { "role": { "documentation": "The nominal value of capital issued." } } }, "auth_ref": [ "r269", "r274" ] }, "ifrs-full_IssuedCapitalMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssuedCapitalMember", "presentation": [ "http://telixpharma.com/role/EquityNarrativeDetails", "http://telixpharma.com/role/EquityScheduleofShareCapitalDetails", "http://telixpharma.com/role/Interimconsolidatedstatementofchangesinequity" ], "lang": { "en-us": { "role": { "terseLabel": "Share capital", "label": "Issued capital [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } } }, "auth_ref": [ "r192" ] }, "ifrs-full_LaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanFiveYearsMember", "presentation": [ "http://telixpharma.com/role/ContractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Over 5 years", "label": "Later than five years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than five years." } } }, "auth_ref": [ "r69", "r70", "r78", "r125", "r129", "r254", "r258", "r260" ] }, "ifrs-full_LaterThanOneMonthAndNotLaterThanSixMonthsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanOneMonthAndNotLaterThanSixMonthsMember", "presentation": [ "http://telixpharma.com/role/ContractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "1-6 months", "label": "Later than one month and not later than six months [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than one month and not later than six months." } } }, "auth_ref": [ "r254", "r260" ] }, "ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanOneYearAndNotLaterThanFiveYearsMember", "presentation": [ "http://telixpharma.com/role/ContractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "1-5 years", "label": "Later than one year and not later than five years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than one year and not later than five years." } } }, "auth_ref": [ "r124", "r128", "r253", "r260" ] }, "ifrs-full_LaterThanOneYearMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanOneYearMember", "presentation": [ "http://telixpharma.com/role/ContingentliabilitiesandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due more than a year", "label": "Later than one year [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than one year." } } }, "auth_ref": [ "r206" ] }, "ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanSixMonthsAndNotLaterThanOneYearMember", "presentation": [ "http://telixpharma.com/role/ContractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "6-12 months", "label": "Later than six months and not later than one year [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than six months and not later than one year." } } }, "auth_ref": [ "r254", "r257", "r260" ] }, "ifrs-full_LeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LeaseLiabilities", "crdr": "credit", "calculation": { "http://telixpharma.com/role/ContractualmaturitiesoffinancialliabilitiesDetails": { "parentTag": "ifrs-full_FinancialLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://telixpharma.com/role/ContractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities, carrying amount", "label": "Lease liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration." } } }, "auth_ref": [ "r65" ] }, "ifrs-full_Level1OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Level1OfFairValueHierarchyMember", "presentation": [ "http://telixpharma.com/role/FairvalueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Level 1 of fair value hierarchy [member]" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date." } } }, "auth_ref": [ "r8", "r18", "r19", "r56", "r152", "r176" ] }, "ifrs-full_Level3OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Level3OfFairValueHierarchyMember", "presentation": [ "http://telixpharma.com/role/FairvalueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 3", "label": "Level 3 of fair value hierarchy [member]" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability." } } }, "auth_ref": [ "r18", "r19", "r56", "r152", "r176" ] }, "ifrs-full_LevelsOfFairValueHierarchyAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LevelsOfFairValueHierarchyAxis", "presentation": [ "http://telixpharma.com/role/FairvalueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Levels of fair value hierarchy [axis]", "label": "Levels of fair value hierarchy [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r8", "r56", "r176" ] }, "ifrs-full_LevelsOfFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LevelsOfFairValueHierarchyDomain", "presentation": [ "http://telixpharma.com/role/FairvalueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Levels of fair value hierarchy [domain]", "label": "Levels of fair value hierarchy [domain]" } }, "en": { "role": { "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used." } } }, "auth_ref": [ "r8", "r56", "r176" ] }, "ifrs-full_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition": { "parentTag": "ifrs-full_NetAssetsLiabilities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition", "http://telixpharma.com/role/SegmentreportingScheduleofOperatingSegmentAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "terseLabel": "Total liabilities", "label": "Liabilities" } }, "en": { "role": { "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r55", "r56", "r57", "r100", "r105", "r175", "r176", "r203" ] }, "ifrs-full_LicencesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LicencesMember", "presentation": [ "http://telixpharma.com/role/IntangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Licenses", "label": "Licences [member]" } }, "en": { "role": { "documentation": "This member stands for a class of intangible assets representing the right to use certain intangible assets owned by another entity. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r284" ] }, "tlx_LightpointMedicalMember": { "xbrltype": "domainItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "LightpointMedicalMember", "presentation": [ "http://telixpharma.com/role/EquityScheduleofShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lightpoint", "label": "Lightpoint Medical [Member]", "documentation": "The name of the entity which is controlled by another entity." } } }, "auth_ref": [] }, "ifrs-full_LongtermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LongtermBorrowings", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 1.0 }, "http://telixpharma.com/role/BorrowingsScheduleofConvertibleBondsDetails": { "parentTag": "ifrs-full_Borrowings", "weight": 1.0, "order": 2.0 }, "http://telixpharma.com/role/BorrowingsScheduleofBorrowingsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://telixpharma.com/role/BorrowingsScheduleofBorrowingsDetails", "http://telixpharma.com/role/BorrowingsScheduleofConvertibleBondsDetails", "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings", "totalLabel": "Borrowings", "netLabel": "Non-current", "label": "Non-current portion of non-current borrowings" } }, "en": { "role": { "documentation": "The non-current portion of non-current borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r297" ] }, "tlx_ManufacturingAndDistributionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "ManufacturingAndDistributionCosts", "crdr": "debit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome", "http://telixpharma.com/role/SegmentreportingScheduleofSegmentPerformanceDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Manufacturing and distribution costs", "label": "Manufacturing And Distribution Costs", "documentation": "The amount of expense relating to manufacturing and distribution of goods and services of the entity." } } }, "auth_ref": [] }, "tlx_ManufacturingSolutionsMember": { "xbrltype": "domainItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "ManufacturingSolutionsMember", "presentation": [ "http://telixpharma.com/role/ProfitandlossinformationScheduleofRevenuefromContractswithCustomersDetails", "http://telixpharma.com/role/SegmentreportingScheduleofOperatingSegmentAssetsandLiabilitiesDetails", "http://telixpharma.com/role/SegmentreportingScheduleofSegmentPerformanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Manufacturing Solutions", "label": "Manufacturing Solutions [Member]", "documentation": "This member stands for a segment which deals with global network of facilities designed to deliver patient doses worldwide and comprises costs to operate company facilities and assets associated with the Group's vertically integrated manufacturing and supply chain." } } }, "auth_ref": [] }, "tlx_MaterialAccountingPolicyInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "MaterialAccountingPolicyInformationAbstract", "lang": { "en-us": { "role": { "terseLabel": "Material accounting policy information [Abstract]", "label": "Material Accounting Policy Information [Abstract]", "documentation": "Material accounting policy information [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_MaterialReconcilingItemsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MaterialReconcilingItemsMember", "presentation": [ "http://telixpharma.com/role/SegmentreportingNarrativeDetails", "http://telixpharma.com/role/SegmentreportingScheduleofOperatingSegmentAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciling items", "label": "Material reconciling items [member]" } }, "en": { "role": { "documentation": "This member stands for material adjustments used to reconcile items in the entity's financial statements." } } }, "auth_ref": [ "r107" ] }, "tlx_MaturityAnalysisForNonDerivativeFinancialLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "MaturityAnalysisForNonDerivativeFinancialLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Maturity Analysis For Non-Derivative Financial Liabilities [Abstract]", "documentation": "Maturity Analysis For Non-Derivative Financial Liabilities [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MaturityAnalysisForNonderivativeFinancialLiabilities", "presentation": [ "http://telixpharma.com/role/ContractualmaturitiesoffinancialliabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Contractual Maturities of Financial Liabilities", "label": "Disclosure of maturity analysis for non-derivative financial liabilities [text block]" } }, "en": { "role": { "documentation": "The disclosure of a maturity analysis for non-derivative financial liabilities (including issued financial guarantee contracts) that shows the remaining contractual maturities. [Refer: Derivative financial liabilities]" } } }, "auth_ref": [ "r91", "r174" ] }, "ifrs-full_MaturityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MaturityAxis", "presentation": [ "http://telixpharma.com/role/ContingentliabilitiesandCommitmentsDetails", "http://telixpharma.com/role/ContractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity [axis]", "label": "Maturity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r63", "r69", "r70", "r71", "r72", "r73", "r78", "r84", "r92", "r116", "r119", "r126", "r130", "r170", "r207", "r230", "r254" ] }, "ifrs-full_MaturityDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MaturityDomain", "presentation": [ "http://telixpharma.com/role/ContingentliabilitiesandCommitmentsDetails", "http://telixpharma.com/role/ContractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity [domain]", "label": "Maturity [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used." } } }, "auth_ref": [ "r63", "r69", "r70", "r71", "r72", "r73", "r78", "r84", "r116", "r119", "r126", "r130", "r170", "r207", "r230", "r254", "r259" ] }, "ifrs-full_NetAssetsLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NetAssetsLiabilities", "crdr": "debit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition", "http://telixpharma.com/role/MaterialaccountingpolicyinformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net assets", "terseLabel": "Net assets", "label": "Assets (liabilities)" } }, "en": { "role": { "documentation": "The amount of assets less the amount of liabilities." } } }, "auth_ref": [ "r244", "r296" ] }, "tlx_NonCurrentContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "NonCurrentContingentConsideration", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration", "label": "Non-Current Contingent Consideration", "documentation": "The non-current portion of non-current contingent consideration." } } }, "auth_ref": [] }, "tlx_NonCurrentEmployeeBenefitObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "NonCurrentEmployeeBenefitObligations", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition" ], "lang": { "en-us": { "role": { "terseLabel": "Employee benefit obligations", "label": "Non-Current Employee Benefit Obligations", "documentation": "The non-current portion of non-current employee benefit obligations." } } }, "auth_ref": [] }, "tlx_NonExecutiveDirectorsFees": { "xbrltype": "monetaryItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "NonExecutiveDirectorsFees", "crdr": "debit", "calculation": { "http://telixpharma.com/role/ProfitandlossinformationScheduleofEmploymentCostsDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://telixpharma.com/role/ProfitandlossinformationScheduleofEmploymentCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Executive Directors\u2019 fees", "label": "Non-Executive Directors Fees", "documentation": "The amount of fees paid or payable to Non-executive directors." } } }, "auth_ref": [] }, "ifrs-full_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentAssets", "crdr": "debit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition" ], "lang": { "en-us": { "role": { "totalLabel": "Total non-current assets", "label": "Non-current assets" } }, "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } } }, "auth_ref": [ "r45", "r208", "r245" ] }, "ifrs-full_NoncurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentAssetsAbstract", "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current assets", "label": "Non-current assets [abstract]" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts", "crdr": "debit", "presentation": [ "http://telixpharma.com/role/SegmentreportingScheduleofGeographicalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current assets by location of asset", "label": "Non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets, and rights arising under insurance contracts" } }, "en": { "role": { "documentation": "The amount of non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets and rights arising under insurance contracts. [Refer: Deferred tax assets; Classes of financial instruments [domain]; Non-current assets]" } } }, "auth_ref": [ "r110" ] }, "ifrs-full_NoncurrentFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentFinancialAssets", "crdr": "debit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition", "http://telixpharma.com/role/SegmentreportingNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial assets", "label": "Non-current financial assets" } }, "en": { "role": { "documentation": "The amount of non-current financial assets. [Refer: Financial assets]" } } }, "auth_ref": [ "r85" ] }, "ifrs-full_NoncurrentLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentLeaseLiabilities", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities", "label": "Non-current lease liabilities" } }, "en": { "role": { "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r65" ] }, "ifrs-full_NoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentLiabilities", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition": { "parentTag": "ifrs-full_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition" ], "lang": { "en-us": { "role": { "totalLabel": "Total non-current liabilities", "label": "Non-current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } } }, "auth_ref": [ "r47", "r209", "r245" ] }, "ifrs-full_NoncurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentLiabilitiesAbstract", "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current liabilities", "label": "Non-current liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentPortionOfNoncurrentBondsIssued": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentPortionOfNoncurrentBondsIssued", "crdr": "credit", "calculation": { "http://telixpharma.com/role/BorrowingsScheduleofBorrowingsDetails": { "parentTag": "tlx_UnsecuredBorrowingsNonCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://telixpharma.com/role/BorrowingsScheduleofBorrowingsDetails", "http://telixpharma.com/role/SegmentreportingNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible bonds", "verboseLabel": "Non-current convertible bonds", "label": "Non-current portion of non-current bonds issued" } }, "en": { "role": { "documentation": "The non-current portion of non-current bonds issued. [Refer: Bonds issued]" } } }, "auth_ref": [ "r296" ] }, "ifrs-full_NoncurrentPortionOfNoncurrentBorrowingsByTypeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentPortionOfNoncurrentBorrowingsByTypeAbstract", "presentation": [ "http://telixpharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current", "label": "Non-current portion of non-current borrowings, by type [abstract]" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentPortionOfNoncurrentSecuredBankLoansReceived": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentPortionOfNoncurrentSecuredBankLoansReceived", "crdr": "credit", "calculation": { "http://telixpharma.com/role/BorrowingsScheduleofBorrowingsDetails": { "parentTag": "tlx_SecuredBorrowingsNonCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://telixpharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current secured bank loans", "label": "Non-current portion of non-current secured bank loans received" } }, "en": { "role": { "documentation": "The non-current portion of non-current secured bank loans received. [Refer: Secured bank loans received]" } } }, "auth_ref": [ "r296" ] }, "ifrs-full_NoncurrentProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentProvisions", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition" ], "lang": { "en-us": { "role": { "verboseLabel": "Provisions", "label": "Non-current provisions" } }, "en": { "role": { "documentation": "The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]" } } }, "auth_ref": [ "r200" ] }, "ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NonderivativeFinancialLiabilitiesUndiscountedCashFlows", "crdr": "credit", "calculation": { "http://telixpharma.com/role/ContractualmaturitiesoffinancialliabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://telixpharma.com/role/ContractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total financial liabilities", "label": "Non-derivative financial liabilities, undiscounted cash flows" } }, "en": { "role": { "documentation": "The amount of contractual undiscounted cash flows in relation to non-derivative financial liabilities." } } }, "auth_ref": [ "r91", "r174" ] }, "ifrs-full_NotLaterThanOneYearMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NotLaterThanOneYearMember", "presentation": [ "http://telixpharma.com/role/ContingentliabilitiesandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due less than a year", "label": "Not later than one year [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of not later than one year." } } }, "auth_ref": [ "r69", "r70", "r78", "r123", "r127", "r205", "r254", "r260" ] }, "ifrs-full_NotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NotionalAmount", "presentation": [ "http://telixpharma.com/role/BorrowingsScheduleofConvertibleBondsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Face value of New Bonds issued", "label": "Notional amount" } }, "en": { "role": { "documentation": "The nominal or face amount of a financial instrument, used to calculate payments made on that instrument." } } }, "auth_ref": [ "r296" ] }, "tlx_NumberOfInitialTherapeuticPrograms": { "xbrltype": "integerItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "NumberOfInitialTherapeuticPrograms", "presentation": [ "http://telixpharma.com/role/ProfitandlossinformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of initial therapeutic programs", "label": "Number Of Initial Therapeutic Programs", "documentation": "Number Of Initial Therapeutic Programs" } } }, "auth_ref": [] }, "tlx_NumberOfSharesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "NumberOfSharesAbstract", "presentation": [ "http://telixpharma.com/role/EquityScheduleofShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Shares [Abstract]", "label": "Number of Shares [Abstract]", "documentation": "Number of Shares" } } }, "auth_ref": [] }, "ifrs-full_NumberOfSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfSharesOutstanding", "presentation": [ "http://telixpharma.com/role/EquityScheduleofShareCapitalDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Number of shares outstanding" } }, "en": { "role": { "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]" } } }, "auth_ref": [ "r134", "r178", "r214" ] }, "tlx_OperatingSegmentAssetsAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "OperatingSegmentAssetsAndLiabilitiesAbstract", "presentation": [ "http://telixpharma.com/role/SegmentreportingScheduleofOperatingSegmentAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Segment Assets and Liabilities [Abstract]", "label": "Operating segment assets and liabilities [Abstract]", "documentation": "Operating segment assets and liabilities [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OperatingSegmentsMember", "presentation": [ "http://telixpharma.com/role/SegmentreportingScheduleofOperatingSegmentAssetsandLiabilitiesDetails", "http://telixpharma.com/role/SegmentreportingScheduleofSegmentPerformanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating segments", "label": "Operating segments [member]" } } }, "auth_ref": [ "r107" ] }, "ifrs-full_OrdinarySharesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OrdinarySharesMember", "presentation": [ "http://telixpharma.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary shares", "label": "Ordinary shares [member]" } }, "en": { "role": { "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments." } } }, "auth_ref": [ "r298" ] }, "ifrs-full_OtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncome", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofchangesinequity": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://telixpharma.com/role/EquityScheduleofOtherReservesDetails", "http://telixpharma.com/role/Interimconsolidatedstatementofchangesinequity" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss)", "netLabel": "Other comprehensive (loss)/income", "label": "Other comprehensive income" } } }, "auth_ref": [ "r50", "r189", "r219", "r226" ] }, "ifrs-full_OtherComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeAbstract", "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income:", "label": "Other comprehensive income [abstract]" } } }, "auth_ref": [] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange differences on translation of foreign operations", "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r210", "r226" ] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in the fair value of investments at fair value through other comprehensive income", "label": "Other comprehensive income, net of tax, gains (losses) from investments in equity instruments" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, related to gains (losses) from changes in the fair value of investments in equity instruments that the entity has designated at fair value through other comprehensive income applying paragraph 5.7.5 of IFRS 9. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r210", "r226" ] }, "ifrs-full_OtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherCurrentAssets", "crdr": "debit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other current assets" } }, "en": { "role": { "documentation": "The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]" } } }, "auth_ref": [ "r297" ] }, "tlx_OtherEquitySecuritiesValueOfConversionRights": { "xbrltype": "monetaryItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "OtherEquitySecuritiesValueOfConversionRights", "crdr": "debit", "presentation": [ "http://telixpharma.com/role/BorrowingsScheduleofConvertibleBondsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other equity securities - value of conversion rights", "label": "Other Equity Securities Value Of Conversion Rights", "documentation": "The increase (decrease) in equity resulting from the conversion of performance rights." } } }, "auth_ref": [] }, "ifrs-full_OtherGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherGainsLosses", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome", "http://telixpharma.com/role/SegmentreportingScheduleofReconciliationofSegmentAdjustedEBITDAtoProfitLossBeforeIncomeTaxesDetails", "http://telixpharma.com/role/SegmentreportingScheduleofSegmentPerformanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other gains/(losses)(net)", "verboseLabel": "Other gains/(losses) (net)", "negatedLabel": "Other (gains)/losses (net)", "label": "Other gains (losses)" } } }, "auth_ref": [ "r291", "r292" ] }, "ifrs-full_OtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherIncome", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome", "http://telixpharma.com/role/ProfitandlossinformationNarrativeDetails", "http://telixpharma.com/role/ProfitandlossinformationScheduleofOtherIncomeDetails", "http://telixpharma.com/role/SegmentreportingScheduleofSegmentPerformanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other income", "negatedLabel": "Other income", "label": "Other income" } } }, "auth_ref": [ "r12", "r270", "r271" ] }, "tlx_OtherNonCurrentLiabilitiesUndiscountedCashFlows": { "xbrltype": "monetaryItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "OtherNonCurrentLiabilitiesUndiscountedCashFlows", "crdr": "credit", "calculation": { "http://telixpharma.com/role/ContractualmaturitiesoffinancialliabilitiesDetails": { "parentTag": "ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://telixpharma.com/role/ContractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current liabilities", "label": "Other Non-Current Liabilities, Undiscounted Cash Flows", "documentation": "Other Non-Current Liabilities, Undiscounted Cash Flows" } } }, "auth_ref": [] }, "ifrs-full_OtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherNoncurrentAssets", "crdr": "debit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current assets", "label": "Other non-current assets" } }, "en": { "role": { "documentation": "The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]" } } }, "auth_ref": [ "r297" ] }, "ifrs-full_OtherNoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherNoncurrentLiabilities", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 4.0 }, "http://telixpharma.com/role/ContractualmaturitiesoffinancialliabilitiesDetails": { "parentTag": "ifrs-full_FinancialLiabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://telixpharma.com/role/ContractualmaturitiesoffinancialliabilitiesDetails", "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current liabilities", "verboseLabel": "Other non-current liabilities, carrying amount", "label": "Other non-current liabilities" } }, "en": { "role": { "documentation": "The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]" } } }, "auth_ref": [ "r297" ] }, "ifrs-full_OtherReserves": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherReserves", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition" ], "lang": { "en-us": { "role": { "terseLabel": "Other reserves", "label": "Other reserves" } }, "en": { "role": { "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]" } } }, "auth_ref": [ "r269", "r274" ] }, "tlx_OtherReservesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "OtherReservesAbstract", "presentation": [ "http://telixpharma.com/role/EquityScheduleofOtherReservesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other reserves [Abstract]", "label": "Other reserves [Abstract]", "documentation": "Other reserves [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_OtherReservesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherReservesMember", "presentation": [ "http://telixpharma.com/role/EquityScheduleofOtherReservesDetails", "http://telixpharma.com/role/Interimconsolidatedstatementofchangesinequity" ], "lang": { "en-us": { "role": { "terseLabel": "Other reserves", "label": "Other reserves [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]" } } }, "auth_ref": [ "r136", "r192" ] }, "ifrs-full_ParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ParValuePerShare", "presentation": [ "http://telixpharma.com/role/EquityScheduleofShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share price (in dollars per share)", "label": "Par value per share" } }, "en": { "role": { "documentation": "The nominal value per share." } } }, "auth_ref": [ "r133", "r177", "r213" ] }, "tlx_PaymentsForContingentConsiderationClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "PaymentsForContingentConsiderationClassifiedAsOperatingActivities", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments for contingent consideration", "label": "Payments For Contingent Consideration, Classified As Operating Activities", "documentation": "The cash outflow for payments to contingent consideration, classified as operating activities." } } }, "auth_ref": [] }, "tlx_PaymentsOfDeferredConsiderationClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "PaymentsOfDeferredConsiderationClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments for deferred consideration", "label": "Payments Of Deferred Consideration, Classified As Investing Activities", "documentation": "Payments Of Deferred Consideration, Classified As Investing Activities" } } }, "auth_ref": [] }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows" ], "lang": { "en-us": { "role": { "negatedLabel": "Principal element of lease payments", "label": "Payments of lease liabilities, classified as financing activities" } }, "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r242" ] }, "ifrs-full_PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PaymentsToSuppliersForGoodsAndServicesAndToAndOnBehalfOfEmployees", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments to suppliers and employees", "label": "Payments to suppliers for goods and services and to and on behalf of employees" } }, "en": { "role": { "documentation": "The cash outflow for payments to suppliers for goods and services and to, and on behalf of, employees." } } }, "auth_ref": [ "r287" ] }, "tlx_PrecisionMedicineMember": { "xbrltype": "domainItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "PrecisionMedicineMember", "presentation": [ "http://telixpharma.com/role/ProfitandlossinformationScheduleofRevenuefromContractswithCustomersDetails", "http://telixpharma.com/role/SegmentreportingScheduleofOperatingSegmentAssetsandLiabilitiesDetails", "http://telixpharma.com/role/SegmentreportingScheduleofSegmentPerformanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Precision Medicine", "label": "Precision Medicine [Member]", "documentation": "This member stands for a segment which deals with is a medical model that separates people into different groups-with medical decisions, practices, interventions and/or products being tailored to the individual patient based on their predicted response or risk of disease. This segment focus on Commercial sales of Illuccix and other diagnostic products subsequent to obtaining regulatory approvals. This segment also includes the development activities of the Group's diagnostic pipeline." } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities", "crdr": "debit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from borrowings", "label": "Proceeds from borrowings, classified as financing activities" } }, "en": { "role": { "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]" } } }, "auth_ref": [ "r240" ] }, "ifrs-full_ProceedsFromIssuingOtherEquityInstruments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromIssuingOtherEquityInstruments", "crdr": "debit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issue of shares and other equity", "label": "Proceeds from issuing other equity instruments" } }, "en": { "role": { "documentation": "The cash inflow from issuing equity instruments that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r239" ] }, "ifrs-full_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 1.0 }, "http://telixpharma.com/role/Interimconsolidatedstatementofchangesinequity": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 1.0 }, "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofchangesinequity", "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome", "http://telixpharma.com/role/MaterialaccountingpolicyinformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Profit/(loss) for the period", "verboseLabel": "Profit (loss) for the period", "terseLabel": "Profit for the period", "label": "Profit (loss)" } }, "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r41", "r43", "r100", "r103", "r151", "r166", "r188", "r218", "r245", "r248" ] }, "ifrs-full_ProfitLossAttributableToAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossAttributableToAbstract", "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome" ], "lang": { "en-us": { "role": { "terseLabel": "Profit/(loss) for the period attributable to:", "label": "Profit (loss), attributable to [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ProfitLossAttributableToOwnersOfParent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossAttributableToOwnersOfParent", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome_1": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome" ], "lang": { "en-us": { "role": { "terseLabel": "Owners of Telix Pharmaceuticals Limited", "label": "Profit (loss), attributable to owners of parent" } }, "en": { "role": { "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r221" ] }, "ifrs-full_ProfitLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossBeforeTax", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome", "http://telixpharma.com/role/SegmentreportingScheduleofReconciliationofSegmentAdjustedEBITDAtoProfitLossBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Profit/(loss) before income tax", "terseLabel": "Profit/(loss) before income tax", "label": "Profit (loss) before tax" } } }, "auth_ref": [ "r82", "r262", "r263", "r270", "r271" ] }, "ifrs-full_ProfitLossFromOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossFromOperatingActivities", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome", "http://telixpharma.com/role/SegmentreportingScheduleofSegmentPerformanceDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Operating profit", "label": "Profit (loss) from operating activities" } } }, "auth_ref": [ "r231", "r299" ] }, "ifrs-full_PropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition", "http://telixpharma.com/role/SegmentreportingNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment", "label": "Property, plant and equipment" } }, "en": { "role": { "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r6", "r147", "r195" ] }, "tlx_PurchaseOfContingentConsiderationClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "PurchaseOfContingentConsiderationClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments for contingent consideration", "label": "Purchase Of Contingent Consideration, Classified As Investing Activities", "documentation": "The cash outflow for the purchase of contingent consideration, classified as investing activities." } } }, "auth_ref": [] }, "ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments for investments in financial assets", "label": "Purchase of financial instruments, classified as investing activities" } }, "en": { "role": { "documentation": "The cash outflow for the purchase of financial instruments. [Refer: Classes of financial instruments [domain]]" } } }, "auth_ref": [ "r288" ] }, "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of intangible assets", "label": "Purchase of intangible assets, classified as investing activities" } }, "en": { "role": { "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r238" ] }, "ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of other non-current assets", "label": "Purchase of other long-term assets, classified as investing activities" } }, "en": { "role": { "documentation": "The cash outflow for the purchases of long-term assets that the entity does not separately disclose in the same statement or note, classified as investing activities. [Refer: Assets]" } } }, "auth_ref": [ "r238" ] }, "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property, plant and equipment", "label": "Purchase of property, plant and equipment, classified as investing activities" } }, "en": { "role": { "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r238" ] }, "tlx_ReceiptsFromCollaborationAgreements": { "xbrltype": "monetaryItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "ReceiptsFromCollaborationAgreements", "crdr": "debit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows" ], "lang": { "en-us": { "role": { "terseLabel": "Receipts from collaboration agreements", "label": "Receipts From Collaboration Agreements", "documentation": "Receipts From Collaboration Agreements" } } }, "auth_ref": [] }, "ifrs-full_ReceiptsFromSalesOfGoodsAndRenderingOfServices": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReceiptsFromSalesOfGoodsAndRenderingOfServices", "crdr": "debit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows" ], "lang": { "en-us": { "role": { "terseLabel": "Receipts from customers", "label": "Receipts from sales of goods and rendering of services" } }, "en": { "role": { "documentation": "The cash inflow from sales of goods and rendering of services." } } }, "auth_ref": [ "r236" ] }, "ifrs-full_ReceivablesFromContractsWithCustomersAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReceivablesFromContractsWithCustomersAbstract", "lang": { "en-us": { "role": { "terseLabel": "Receivables from contracts with customers [abstract]", "label": "Receivables from contracts with customers [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract", "presentation": [ "http://telixpharma.com/role/IntangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of changes in intangible assets other than goodwill [abstract]", "label": "Reconciliation of changes in intangible assets other than goodwill [abstract]" } } }, "auth_ref": [] }, "tlx_ReconciliationOfTotalSegmentAdjustedEBITDAAndGroupAdjustedEBITAToProfitLossBeforeIncomeTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "ReconciliationOfTotalSegmentAdjustedEBITDAAndGroupAdjustedEBITAToProfitLossBeforeIncomeTaxAbstract", "presentation": [ "http://telixpharma.com/role/SegmentreportingScheduleofReconciliationofSegmentAdjustedEBITDAtoProfitLossBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Total Segment Adjusted EBITDA and Group Adjusted EBITA to Profit/(Loss) Before Income Tax [Abstract]", "label": "Reconciliation Of Total Segment Adjusted EBITDA And Group Adjusted EBITA To Profit/Loss) Before Income Tax [Abstract]", "documentation": "Reconciliation of total segment adjusted EBITDA and group adjusted EBITA to profit/(loss) before income tax [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RepaymentsOfBorrowingsClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcashflows" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayment of borrowings", "label": "Repayments of borrowings, classified as financing activities" } }, "en": { "role": { "documentation": "The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]" } } }, "auth_ref": [ "r241" ] }, "tlx_RepurchaseOfConvertibleBonds": { "xbrltype": "monetaryItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "RepurchaseOfConvertibleBonds", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofchangesinequity": { "parentTag": "ifrs-full_ChangesInEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://telixpharma.com/role/BorrowingsScheduleofConvertibleBondsDetails", "http://telixpharma.com/role/Interimconsolidatedstatementofchangesinequity" ], "lang": { "en-us": { "role": { "terseLabel": "Repurchase of convertible bonds", "negatedTerseLabel": "Repurchase of Existing Bonds", "label": "Repurchase Of Convertible Bonds", "documentation": "Repurchase Of Convertible Bonds" } } }, "auth_ref": [] }, "tlx_RepurchasedBondsAsAPercentageOfExistingBonds": { "xbrltype": "percentItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "RepurchasedBondsAsAPercentageOfExistingBonds", "presentation": [ "http://telixpharma.com/role/BorrowingsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repurchased bonds as a percentage of existing bonds", "label": "Repurchased Bonds As A Percentage Of Existing Bonds", "documentation": "Repurchased Bonds As A Percentage Of Existing Bonds" } } }, "auth_ref": [] }, "ifrs-full_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome", "http://telixpharma.com/role/SegmentreportingScheduleofSegmentPerformanceDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Research and development costs", "label": "Research and development expense" } } }, "auth_ref": [ "r26", "r159" ] }, "tlx_ResearchAndDevelopmentsCommitmentsContractualObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "ResearchAndDevelopmentsCommitmentsContractualObligations", "crdr": "credit", "presentation": [ "http://telixpharma.com/role/ContingentliabilitiesandCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "R&D commitments", "label": "Research And Developments Commitments Contractual Obligations", "documentation": "The amount of research and developments commitments contractual obligations for which the entity has committed." } } }, "auth_ref": [] }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReserveOfExchangeDifferencesOnTranslationMember", "presentation": [ "http://telixpharma.com/role/EquityScheduleofOtherReservesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation reserve", "label": "Reserve of exchange differences on translation [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r10", "r148", "r272" ] }, "ifrs-full_ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember", "presentation": [ "http://telixpharma.com/role/EquityScheduleofOtherReservesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial assets at FVOCI reserve", "label": "Reserve of gains and losses on financial assets measured at fair value through other comprehensive income [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing the accumulated gains and losses on financial assets measured at fair value through other comprehensive income. [Refer: Financial assets measured at fair value through other comprehensive income; Other comprehensive income]" } } }, "auth_ref": [ "r272" ] }, "ifrs-full_ReserveOfSharebasedPaymentsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReserveOfSharebasedPaymentsMember", "presentation": [ "http://telixpharma.com/role/EquityScheduleofOtherReservesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payments reserve", "label": "Reserve of share-based payments [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity resulting from share-based payments." } } }, "auth_ref": [ "r272" ] }, "ifrs-full_RetainedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarnings", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated losses", "label": "Retained earnings" } }, "en": { "role": { "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r269", "r274", "r275" ] }, "ifrs-full_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarningsMember", "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofchangesinequity" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated losses", "label": "Retained earnings [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r192", "r272" ] }, "ifrs-full_Revenue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Revenue", "crdr": "credit", "calculation": { "http://telixpharma.com/role/ProfitandlossinformationScheduleofRevenuefromContractswithCustomersDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://telixpharma.com/role/ProfitandlossinformationScheduleofRevenuefromContractswithCustomersDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total revenue from continuing operations", "label": "Revenue" } } }, "auth_ref": [ "r49", "r82", "r96", "r102", "r108", "r109", "r112", "r223", "r245", "r270", "r271" ] }, "ifrs-full_RevenueFromContractsWithCustomers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RevenueFromContractsWithCustomers", "crdr": "credit", "calculation": { "http://telixpharma.com/role/SegmentreportingScheduleofSegmentPerformanceDetails": { "parentTag": "ifrs-full_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome", "http://telixpharma.com/role/SegmentreportingScheduleofGeographicalInformationDetails", "http://telixpharma.com/role/SegmentreportingScheduleofSegmentPerformanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from contracts with customers", "verboseLabel": "Revenue by location of customer", "label": "Revenue from contracts with customers" } } }, "auth_ref": [ "r60", "r61", "r117" ] }, "ifrs-full_RevenueFromRenderingOfServices": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RevenueFromRenderingOfServices", "crdr": "credit", "calculation": { "http://telixpharma.com/role/ProfitandlossinformationScheduleofRevenuefromContractswithCustomersDetails": { "parentTag": "ifrs-full_Revenue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://telixpharma.com/role/ProfitandlossinformationScheduleofRevenuefromContractswithCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provision of services", "label": "Revenue from rendering of services" } } }, "auth_ref": [ "r296" ] }, "tlx_RevenueFromResearchAndDevelopmentServices": { "xbrltype": "monetaryItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "RevenueFromResearchAndDevelopmentServices", "crdr": "credit", "calculation": { "http://telixpharma.com/role/ProfitandlossinformationScheduleofRevenuefromContractswithCustomersDetails": { "parentTag": "ifrs-full_Revenue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://telixpharma.com/role/ProfitandlossinformationScheduleofRevenuefromContractswithCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development services", "label": "Revenue From Research And Development Services", "documentation": "The amount of income arising from research and development services." } } }, "auth_ref": [] }, "ifrs-full_RevenueFromRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RevenueFromRoyalties", "crdr": "credit", "calculation": { "http://telixpharma.com/role/ProfitandlossinformationScheduleofRevenuefromContractswithCustomersDetails": { "parentTag": "ifrs-full_Revenue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://telixpharma.com/role/ProfitandlossinformationScheduleofRevenuefromContractswithCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty income", "label": "Royalty income" } } }, "auth_ref": [ "r296" ] }, "ifrs-full_RevenueFromSaleOfGoods": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RevenueFromSaleOfGoods", "crdr": "credit", "calculation": { "http://telixpharma.com/role/ProfitandlossinformationScheduleofRevenuefromContractswithCustomersDetails": { "parentTag": "ifrs-full_Revenue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://telixpharma.com/role/ProfitandlossinformationScheduleofRevenuefromContractswithCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of goods", "label": "Revenue from sale of goods" } } }, "auth_ref": [ "r296" ] }, "ifrs-full_RightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RightofuseAssets", "crdr": "debit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets", "label": "Right-of-use assets" } }, "en": { "role": { "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee." } } }, "auth_ref": [ "r64", "r67", "r121" ] }, "ifrs-full_SalesAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SalesAndMarketingExpense", "crdr": "debit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofcomprehensiveincome", "http://telixpharma.com/role/SegmentreportingScheduleofSegmentPerformanceDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Selling and marketing expenses", "label": "Sales and marketing expense" } } }, "auth_ref": [ "r299" ] }, "tlx_SalesCommissions": { "xbrltype": "monetaryItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "SalesCommissions", "crdr": "debit", "calculation": { "http://telixpharma.com/role/ProfitandlossinformationScheduleofEmploymentCostsDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://telixpharma.com/role/ProfitandlossinformationScheduleofEmploymentCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales commissions", "label": "Sales Commissions", "documentation": "The amount of expense arising from sales commissions." } } }, "auth_ref": [] }, "tlx_SalesVolumeRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "SalesVolumeRiskMember", "presentation": [ "http://telixpharma.com/role/FairvalueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales volume risk", "label": "Sales Volume Risk [Member]", "documentation": "Sales Volume Risk" } } }, "auth_ref": [] }, "tlx_ScheduleOfDisclosureOfDepreciationAndAmortizationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "ScheduleOfDisclosureOfDepreciationAndAmortizationTextBlock", "presentation": [ "http://telixpharma.com/role/ProfitandlossinformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Depreciation and Amortization", "label": "Schedule Of Disclosure of Depreciation And Amortization [Text Block]", "documentation": "Schedule Of Disclosure of Depreciation And Amortization" } } }, "auth_ref": [] }, "tlx_SecuredBorrowingsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "SecuredBorrowingsCurrent", "crdr": "credit", "calculation": { "http://telixpharma.com/role/BorrowingsScheduleofBorrowingsDetails": { "parentTag": "ifrs-full_ShorttermBorrowings", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://telixpharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total secured borrowings current", "label": "Secured Borrowings, Current", "documentation": "long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower." } } }, "auth_ref": [] }, "tlx_SecuredBorrowingsNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "SecuredBorrowingsNonCurrent", "crdr": "credit", "calculation": { "http://telixpharma.com/role/BorrowingsScheduleofBorrowingsDetails": { "parentTag": "ifrs-full_LongtermBorrowings", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://telixpharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total secured borrowings non current", "label": "Secured Borrowings, Non Current", "documentation": "The amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets." } } }, "auth_ref": [] }, "tlx_SecuredWorkingCapitalFacilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "SecuredWorkingCapitalFacilityCurrent", "crdr": "debit", "calculation": { "http://telixpharma.com/role/BorrowingsScheduleofBorrowingsDetails": { "parentTag": "tlx_SecuredBorrowingsCurrent", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://telixpharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Current secured working capital facility", "label": "Secured Working Capital Facility, Current", "documentation": "The amount of current secured working capital facility current received and the current portion of non-current secured working capital facility current received." } } }, "auth_ref": [] }, "tlx_SecuredWorkingCapitalFacilityNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "SecuredWorkingCapitalFacilityNonCurrent", "crdr": "debit", "calculation": { "http://telixpharma.com/role/BorrowingsScheduleofBorrowingsDetails": { "parentTag": "tlx_SecuredBorrowingsNonCurrent", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://telixpharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Non-current secured working capital facility", "label": "Secured Working Capital Facility, Non-Current", "documentation": "The non-current portion of non-current secured working capital facility received." } } }, "auth_ref": [] }, "ifrs-full_SegmentConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SegmentConsolidationItemsAxis", "presentation": [ "http://telixpharma.com/role/SegmentreportingNarrativeDetails", "http://telixpharma.com/role/SegmentreportingScheduleofOperatingSegmentAssetsandLiabilitiesDetails", "http://telixpharma.com/role/SegmentreportingScheduleofReconciliationofSegmentAdjustedEBITDAtoProfitLossBeforeIncomeTaxesDetails", "http://telixpharma.com/role/SegmentreportingScheduleofSegmentPerformanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment consolidation items [axis]", "label": "Segment consolidation items [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r100" ] }, "ifrs-full_SegmentConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SegmentConsolidationItemsDomain", "presentation": [ "http://telixpharma.com/role/SegmentreportingNarrativeDetails", "http://telixpharma.com/role/SegmentreportingScheduleofOperatingSegmentAssetsandLiabilitiesDetails", "http://telixpharma.com/role/SegmentreportingScheduleofReconciliationofSegmentAdjustedEBITDAtoProfitLossBeforeIncomeTaxesDetails", "http://telixpharma.com/role/SegmentreportingScheduleofSegmentPerformanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment consolidation items [domain]", "label": "Segment consolidation items [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Segment consolidation items' axis if no other member is used." } } }, "auth_ref": [ "r107" ] }, "ifrs-full_SegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SegmentsAxis", "presentation": [ "http://telixpharma.com/role/ProfitandlossinformationScheduleofRevenuefromContractswithCustomersDetails", "http://telixpharma.com/role/SegmentreportingScheduleofOperatingSegmentAssetsandLiabilitiesDetails", "http://telixpharma.com/role/SegmentreportingScheduleofSegmentPerformanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [axis]", "label": "Segments [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r17", "r62", "r100", "r118", "r229", "r250" ] }, "ifrs-full_SegmentsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SegmentsDomain", "presentation": [ "http://telixpharma.com/role/ProfitandlossinformationScheduleofRevenuefromContractswithCustomersDetails", "http://telixpharma.com/role/SegmentreportingScheduleofOperatingSegmentAssetsandLiabilitiesDetails", "http://telixpharma.com/role/SegmentreportingScheduleofSegmentPerformanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [domain]", "label": "Segments [domain]" } }, "en": { "role": { "documentation": "This member stands for all segments of an entity. It also represents the standard value for the 'Segments' axis if no other member is used." } } }, "auth_ref": [ "r17", "r62", "r107", "r118", "r229", "r250" ] }, "tlx_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnOtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnOtherComprehensiveIncome", "crdr": "credit", "presentation": [ "http://telixpharma.com/role/FairvalueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Movement in other comprehensive income", "label": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Impact On Other Comprehensive Income", "documentation": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Impact On Other Comprehensive Income" } } }, "auth_ref": [] }, "tlx_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings", "crdr": "credit", "presentation": [ "http://telixpharma.com/role/FairvalueDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Movement in profit before tax", "label": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Impact On Pre-Tax Earnings", "documentation": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Impact On Pre-Tax Earnings" } } }, "auth_ref": [] }, "tlx_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariablePercent": { "xbrltype": "percentItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariablePercent", "presentation": [ "http://telixpharma.com/role/FairvalueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in risk variable, percent", "label": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Percent", "documentation": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Percent" } } }, "auth_ref": [] }, "tlx_SharesIssuedThroughExerciseOfShareOptionsAndWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "SharesIssuedThroughExerciseOfShareOptionsAndWarrants", "crdr": "credit", "presentation": [ "http://telixpharma.com/role/EquityScheduleofShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued through the exercise of share options and warrants", "label": "Shares Issued Through Exercise Of Share Options And Warrants", "documentation": "Value of shares issued as a result of the exercise of stock options and warrants." } } }, "auth_ref": [] }, "ifrs-full_ShorttermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShorttermBorrowings", "crdr": "credit", "calculation": { "http://telixpharma.com/role/BorrowingsScheduleofConvertibleBondsDetails": { "parentTag": "ifrs-full_Borrowings", "weight": 1.0, "order": 1.0 }, "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 2.0 }, "http://telixpharma.com/role/BorrowingsScheduleofBorrowingsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://telixpharma.com/role/BorrowingsScheduleofBorrowingsDetails", "http://telixpharma.com/role/BorrowingsScheduleofConvertibleBondsDetails", "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings", "totalLabel": "Total borrowings current", "netLabel": "Current", "label": "Current borrowings" } }, "en": { "role": { "documentation": "The amount of current borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r297" ] }, "ifrs-full_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of cash flows [abstract]", "label": "Statement of cash flows [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of changes in equity [abstract]", "label": "Statement of changes in equity [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityLineItems", "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofchangesinequity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of changes in equity [line items]", "label": "Statement of changes in equity [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityTable", "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementofchangesinequity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of changes in equity [table]", "label": "Statement of changes in equity [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } } }, "auth_ref": [ "r192" ] }, "ifrs-full_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of financial position [abstract]", "label": "Statement of financial position [abstract]" } } }, "auth_ref": [] }, "tlx_TherapeuticsMember": { "xbrltype": "domainItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "TherapeuticsMember", "presentation": [ "http://telixpharma.com/role/ProfitandlossinformationScheduleofRevenuefromContractswithCustomersDetails", "http://telixpharma.com/role/SegmentreportingScheduleofOperatingSegmentAssetsandLiabilitiesDetails", "http://telixpharma.com/role/SegmentreportingScheduleofSegmentPerformanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Therapeutics", "label": "Therapeutics [Member]", "documentation": "This member stands for a medical segment which deals of medicine concerned with the treatment of disease and the action of remedial agents. The Therapeutics segment focuses on the development of company core therapeutic pipeline for commercialization. This segment includes revenue received from license agreements prior to commercialization and research and development services. This segment includes the development activities of the Group's pivotal therapeutic pipeline." } } }, "auth_ref": [] }, "ifrs-full_TimingOfTransferOfGoodsOrServicesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TimingOfTransferOfGoodsOrServicesAxis", "presentation": [ "http://telixpharma.com/role/ProfitandlossinformationScheduleofRevenuefromContractswithCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Timing of transfer of goods or services [axis]", "label": "Timing of transfer of goods or services [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r247", "r267" ] }, "ifrs-full_TimingOfTransferOfGoodsOrServicesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TimingOfTransferOfGoodsOrServicesDomain", "presentation": [ "http://telixpharma.com/role/ProfitandlossinformationScheduleofRevenuefromContractswithCustomersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Timing of transfer of goods or services [domain]", "label": "Timing of transfer of goods or services [domain]" } }, "en": { "role": { "documentation": "This member stands for all timings of the transfer of goods or services in contracts with customers. It also represents the standard value for the 'Timing of transfer of goods or services' axis if no other member is used." } } }, "auth_ref": [ "r247", "r267" ] }, "ifrs-full_TradeAndOtherCurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentPayables", "crdr": "credit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 1.0 }, "http://telixpharma.com/role/ContractualmaturitiesoffinancialliabilitiesDetails": { "parentTag": "ifrs-full_FinancialLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://telixpharma.com/role/ContractualmaturitiesoffinancialliabilitiesDetails", "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition" ], "lang": { "en-us": { "role": { "terseLabel": "Trade and other payables", "verboseLabel": "Trade and other payables, carrying amount", "label": "Trade and other current payables" } }, "en": { "role": { "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]" } } }, "auth_ref": [ "r199" ] }, "ifrs-full_TradeAndOtherCurrentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentReceivables", "crdr": "debit", "calculation": { "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://telixpharma.com/role/Interimconsolidatedstatementoffinancialposition" ], "lang": { "en-us": { "role": { "terseLabel": "Trade and other receivables", "label": "Trade and other current receivables" } }, "en": { "role": { "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]" } } }, "auth_ref": [ "r183", "r197", "r211" ] }, "ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherPayablesUndiscountedCashFlows", "crdr": "credit", "calculation": { "http://telixpharma.com/role/ContractualmaturitiesoffinancialliabilitiesDetails": { "parentTag": "ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://telixpharma.com/role/ContractualmaturitiesoffinancialliabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade and other payables", "label": "Trade and other payables, undiscounted cash flows" } }, "en": { "role": { "documentation": "The amount of contractual undiscounted cash flows in relation to trade and other payables. [Refer: Trade and other payables]" } } }, "auth_ref": [ "r256", "r260" ] }, "ifrs-full_TypesOfRisksAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfRisksAxis", "presentation": [ "http://telixpharma.com/role/FairvalueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of risks [axis]", "label": "Types of risks [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r11", "r74", "r75", "r76", "r77", "r83", "r86", "r87", "r149" ] }, "ifrs-full_TypesOfRisksDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfRisksDomain", "presentation": [ "http://telixpharma.com/role/FairvalueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of risks [domain]", "label": "Types of risks [domain]" } }, "en": { "role": { "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used." } } }, "auth_ref": [ "r11", "r74", "r75", "r76", "r77", "r83", "r86", "r87", "r149" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2025", "localname": "US", "presentation": [ "http://telixpharma.com/role/SegmentreportingScheduleofGeographicalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "United States", "label": "UNITED STATES" } } }, "auth_ref": [] }, "ifrs-full_UnallocatedAmountsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UnallocatedAmountsMember", "presentation": [ "http://telixpharma.com/role/SegmentreportingNarrativeDetails", "http://telixpharma.com/role/SegmentreportingScheduleofReconciliationofSegmentAdjustedEBITDAtoProfitLossBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Unallocated income, expenses and eliminations:", "label": "Unallocated amounts [member]" } }, "en": { "role": { "documentation": "This member stands for items that have not been allocated to operating segments." } } }, "auth_ref": [ "r264", "r265" ] }, "tlx_UnallocatedIncomeExpensesAndEliminationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "UnallocatedIncomeExpensesAndEliminationsAbstract", "presentation": [ "http://telixpharma.com/role/SegmentreportingScheduleofReconciliationofSegmentAdjustedEBITDAtoProfitLossBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unallocated income, expenses and eliminations:", "label": "Unallocated income, expenses and eliminations [Abstract]", "documentation": "Unallocated income, expenses and eliminations [Abstract]" } } }, "auth_ref": [] }, "tlx_UnsecuredBorrowingsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "UnsecuredBorrowingsCurrent", "crdr": "credit", "calculation": { "http://telixpharma.com/role/BorrowingsScheduleofBorrowingsDetails": { "parentTag": "ifrs-full_ShorttermBorrowings", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://telixpharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total unsecured borrowings current", "label": "Unsecured Borrowings, Current", "documentation": "long-term, uncollateralized debt obligations due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "tlx_UnsecuredBorrowingsNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "UnsecuredBorrowingsNonCurrent", "crdr": "credit", "calculation": { "http://telixpharma.com/role/BorrowingsScheduleofBorrowingsDetails": { "parentTag": "ifrs-full_LongtermBorrowings", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://telixpharma.com/role/BorrowingsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total unsecured borrowings non current", "label": "Unsecured Borrowings, Non-Current", "documentation": "The amount of uncollateralized debt obligation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion." } } }, "auth_ref": [] }, "tlx_UnwindOfDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "UnwindOfDiscount", "crdr": "debit", "calculation": { "http://telixpharma.com/role/ProfitandlossinformationScheduleofFinanceCostsDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://telixpharma.com/role/BorrowingsScheduleofConvertibleBondsDetails", "http://telixpharma.com/role/ProfitandlossinformationScheduleofFinanceCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unwind of discount", "label": "Unwind Of Discount", "documentation": "The amount of unwind of discount in finance cost." } } }, "auth_ref": [] }, "tlx_ValueOfShareholdingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "ValueOfShareholdingAbstract", "presentation": [ "http://telixpharma.com/role/EquityScheduleofShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Value of Shareholding [Abstract]", "label": "Value of Shareholding [Abstract]", "documentation": "Value of Shareholding" } } }, "auth_ref": [] }, "tlx_VolumeWeightedAveragePeriod": { "xbrltype": "durationItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "VolumeWeightedAveragePeriod", "presentation": [ "http://telixpharma.com/role/EquityScheduleofShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Volume weighted average period", "label": "Volume Weighted Average Period", "documentation": "Volume weighted average period in in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "tlx_VolumeWeightedAveragePriceOfEquityInstruments": { "xbrltype": "perShareItemType", "nsuri": "http://telixpharma.com/20260630", "localname": "VolumeWeightedAveragePriceOfEquityInstruments", "presentation": [ "http://telixpharma.com/role/EquityScheduleofShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Volume weighted average price (in dollars per share)", "label": "Volume Weighted Average Price Of Equity Instruments", "documentation": "The 10-day volume weighted average price of other equity instruments." } } }, "auth_ref": [] }, "ifrs-full_WagesAndSalaries": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WagesAndSalaries", "crdr": "debit", "calculation": { "http://telixpharma.com/role/ProfitandlossinformationScheduleofEmploymentCostsDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://telixpharma.com/role/ProfitandlossinformationNarrativeDetails", "http://telixpharma.com/role/ProfitandlossinformationScheduleofEmploymentCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Salaries and wages", "label": "Wages and salaries" } } }, "auth_ref": [ "r278" ] }, "ifrs-full_WeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageShares", "presentation": [ "http://telixpharma.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of ordinary shares used as the denominator in calculating basic earnings/loss per share (in shares)", "label": "Weighted average number of ordinary shares used in calculating basic earnings per share" } }, "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } } }, "auth_ref": [ "r16" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "10", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI", "URIDate": "2025-03-27" }, "r1": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_79&doctype=Standard", "URIDate": "2025-03-27" }, "r2": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2025-03-27" }, "r3": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r4": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "g", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_g_i&doctype=Standard", "URIDate": "2025-03-27" }, "r5": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2025-03-27" }, "r6": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2025-03-27" }, "r7": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "75", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_75_b&doctype=Standard", "URIDate": "2025-03-27" }, "r8": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "142", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_142&doctype=Standard", "URIDate": "2025-03-27" }, "r9": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "36", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2025-en-r&anchor=para_36_b&doctype=Standard", "URIDate": "2025-03-27" }, "r10": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2025-01-01", "Paragraph": "52", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_52_b&doctype=Standard", "URIDate": "2025-03-27" }, "r11": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2025-01-01", "Paragraph": "A19", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_A19_f&doctype=Standard", "URIDate": "2025-03-27" }, "r12": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2025-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2025-en-r&anchor=para_35_b_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r13": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2025-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2025-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2025-03-27" }, "r14": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r15": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_67&doctype=Standard", "URIDate": "2025-03-27" }, "r16": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2025-03-27" }, "r17": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "130", "Subparagraph": "d", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_130_d_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r18": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "130", "Subparagraph": "f", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_130_f_i&doctype=Standard", "URIDate": "2025-03-27" }, "r19": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "134", "Subparagraph": "e", "Clause": "iiA", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_134_e_iiA&doctype=Standard", "URIDate": "2025-03-27" }, "r20": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2025-03-27" }, "r21": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_i&doctype=Standard", "URIDate": "2025-03-27" }, "r22": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r23": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r24": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2025-03-27" }, "r25": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118&doctype=Standard", "URIDate": "2025-03-27" }, "r26": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_126&doctype=Standard", "URIDate": "2025-03-27" }, "r27": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "76", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_76&doctype=Standard", "URIDate": "2025-03-27" }, "r28": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2025-03-27" }, "r29": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_79_d&doctype=Standard", "URIDate": "2025-03-27" }, "r30": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2025-01-01", "Paragraph": "50", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_50&doctype=Standard", "URIDate": "2025-03-27" }, "r31": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2025-03-27" }, "r32": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_10&doctype=Standard", "URIDate": "2025-03-27" }, "r33": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard", "URIDate": "2025-03-27" }, "r34": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_28&doctype=Standard", "URIDate": "2025-03-27" }, "r35": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard", "URIDate": "2025-03-27" }, "r36": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35&doctype=Standard", "URIDate": "2025-03-27" }, "r37": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "39", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_39&doctype=Standard", "URIDate": "2025-03-27" }, "r38": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r39": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "50", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2025-03-27" }, "r40": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2025-03-27" }, "r41": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2025-03-27" }, "r42": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r43": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r44": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r45": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r46": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r47": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r48": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ix", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r49": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r50": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r51": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r52": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_d&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r53": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r54": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r55": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2025-03-27" }, "r56": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2025-03-27" }, "r57": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2025-03-27" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS13_g91-99_TI", "URIDate": "2025-03-27" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "105", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_105&doctype=Standard", "URIDate": "2025-03-27" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "113", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_113_a&doctype=Standard", "URIDate": "2025-03-27" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "114", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_114&doctype=Standard", "URIDate": "2025-03-27" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "115", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_115&doctype=Standard", "URIDate": "2025-03-27" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "120", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_120_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2025-03-27" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2025-03-27" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_b&doctype=Standard", "URIDate": "2025-03-27" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "Subparagraph": "j", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_j&doctype=Standard", "URIDate": "2025-03-27" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "58", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_58&doctype=Standard", "URIDate": "2025-03-27" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "94", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_94&doctype=Standard", "URIDate": "2025-03-27" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "97", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_97&doctype=Standard", "URIDate": "2025-03-27" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "109", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_109&doctype=Standard", "URIDate": "2025-03-27" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "109A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_109A&doctype=Standard", "URIDate": "2025-03-27" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "120", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_120&doctype=Standard", "URIDate": "2025-03-27" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "124", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_124&doctype=Standard", "URIDate": "2025-03-27" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "125", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_125&doctype=Standard", "URIDate": "2025-03-27" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_127&doctype=Standard", "URIDate": "2025-03-27" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "128", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_128_a&doctype=Standard", "URIDate": "2025-03-27" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "132", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_132_b&doctype=Standard", "URIDate": "2025-03-27" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "B64", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B64&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "B67", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "B67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B67&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "21C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_21C&doctype=Standard", "URIDate": "2025-03-27" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "23B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_23B_a&doctype=Standard", "URIDate": "2025-03-27" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard", "URIDate": "2025-03-27" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_33&doctype=Standard", "URIDate": "2025-03-27" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_34&doctype=Standard", "URIDate": "2025-03-27" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35H", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2025-03-27" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35I&doctype=Standard", "URIDate": "2025-03-27" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2025-03-27" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "39", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_39_a&doctype=Standard", "URIDate": "2025-03-27" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "42E", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_42E_e&doctype=Standard", "URIDate": "2025-03-27" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "42I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_42I&doctype=Standard", "URIDate": "2025-03-27" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_6&doctype=Standard", "URIDate": "2025-03-27" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_7&doctype=Standard", "URIDate": "2025-03-27" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_a&doctype=Standard", "URIDate": "2025-03-27" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_d&doctype=Standard", "URIDate": "2025-03-27" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_e&doctype=Standard", "URIDate": "2025-03-27" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2025-03-27" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard", "URIDate": "2025-03-27" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2025-03-27" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_a&doctype=Standard", "URIDate": "2025-03-27" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2025-03-27" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2025-03-27" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_d&doctype=Standard", "URIDate": "2025-03-27" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_e&doctype=Standard", "URIDate": "2025-03-27" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28&doctype=Standard", "URIDate": "2025-03-27" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_32&doctype=Standard", "URIDate": "2025-03-27" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_33_a&doctype=Standard", "URIDate": "2025-03-27" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2025-03-27" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_33&doctype=Standard", "URIDate": "2025-03-27" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_34&doctype=Standard", "URIDate": "2025-03-27" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS08_g20-24_TI", "URIDate": "2025-03-27" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "9", "IssueDate": "2025-01-01", "Paragraph": "7.2.34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_7.2.34&doctype=Standard", "URIDate": "2025-03-27" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "9", "IssueDate": "2025-01-01", "Paragraph": "7.2.42", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_7.2.42&doctype=Standard", "URIDate": "2025-03-27" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2026-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "30A", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_30A_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103&doctype=Standard", "URIDate": "2025-03-27" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_104&doctype=Standard", "URIDate": "2025-03-27" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "108", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_108_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_b&doctype=Standard", "URIDate": "2025-03-27" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_i&doctype=Standard", "URIDate": "2025-03-27" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "119", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_119&doctype=Standard", "URIDate": "2025-03-27" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "122", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "122", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "122", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "122", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a&doctype=Standard", "URIDate": "2025-03-27" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "124", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124_a&doctype=Standard", "URIDate": "2025-03-27" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "124", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124_b&doctype=Standard", "URIDate": "2025-03-27" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "124", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124_c&doctype=Standard", "URIDate": "2025-03-27" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "124", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124&doctype=Standard", "URIDate": "2025-03-27" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "128", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_128&doctype=Standard", "URIDate": "2025-03-27" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "133", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_133_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a&doctype=Standard", "URIDate": "2025-03-27" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_b&doctype=Standard", "URIDate": "2025-03-27" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160&doctype=Standard", "URIDate": "2025-03-27" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "164", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_164_b&doctype=Standard", "URIDate": "2025-03-27" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "166", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_166&doctype=Standard", "URIDate": "2025-03-27" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "169", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_169&doctype=Standard", "URIDate": "2025-03-27" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "176", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_176&doctype=Standard", "URIDate": "2025-03-27" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "192", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_192&doctype=Standard", "URIDate": "2025-03-27" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_i&doctype=Standard", "URIDate": "2025-03-27" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "f", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_f_i&doctype=Standard", "URIDate": "2025-03-27" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_d&doctype=Standard", "URIDate": "2025-03-27" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e&doctype=Standard", "URIDate": "2025-03-27" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "218", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_218_b&doctype=Standard", "URIDate": "2025-03-27" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "223", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_223_f&doctype=Standard", "URIDate": "2025-03-27" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2025-03-27" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2025-03-27" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "254", "Subparagraph": "e", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_254_e_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_c&doctype=Standard", "URIDate": "2025-03-27" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e_i&doctype=Standard", "URIDate": "2025-03-27" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "e", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "e", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e&doctype=Standard", "URIDate": "2025-03-27" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263&doctype=Standard", "URIDate": "2025-03-27" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "266", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_266&doctype=Standard", "URIDate": "2025-03-27" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "269", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_269&doctype=Standard", "URIDate": "2025-03-27" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "271", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_271_c&doctype=Standard", "URIDate": "2025-03-27" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "271", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_271_d&doctype=Standard", "URIDate": "2025-03-27" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "273", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_273&doctype=Standard", "URIDate": "2025-03-27" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "274", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_274_e&doctype=Standard", "URIDate": "2025-03-27" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_35&doctype=Standard", "URIDate": "2025-03-27" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_37&doctype=Standard", "URIDate": "2025-03-27" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "43", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_43&doctype=Standard", "URIDate": "2025-03-27" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "64A", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_64A_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_70&doctype=Standard", "URIDate": "2025-03-27" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "71", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_71&doctype=Standard", "URIDate": "2025-03-27" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "72", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_72_a&doctype=Standard", "URIDate": "2025-03-27" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_a&doctype=Standard", "URIDate": "2025-03-27" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_b&doctype=Standard", "URIDate": "2025-03-27" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_iii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_iv&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B13", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B13&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_103&doctype=Standard", "URIDate": "2025-03-27" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_104&doctype=Standard", "URIDate": "2025-03-27" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_a&doctype=Standard", "URIDate": "2025-03-27" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_i&doctype=Standard", "URIDate": "2025-03-27" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d&doctype=Standard", "URIDate": "2025-03-27" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106&doctype=Standard", "URIDate": "2025-03-27" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_117&doctype=Standard", "URIDate": "2025-03-27" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "51", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_51&doctype=Standard", "URIDate": "2025-03-27" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_a&doctype=Standard", "URIDate": "2025-03-27" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_g&doctype=Standard", "URIDate": "2025-03-27" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_h&doctype=Standard", "URIDate": "2025-03-27" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_i&doctype=Standard", "URIDate": "2025-03-27" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "k", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_k&doctype=Standard", "URIDate": "2025-03-27" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "l", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_l&doctype=Standard", "URIDate": "2025-03-27" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "n", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_n&doctype=Standard", "URIDate": "2025-03-27" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "o", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_o&doctype=Standard", "URIDate": "2025-03-27" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard", "URIDate": "2025-03-27" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "56", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_56&doctype=Standard", "URIDate": "2025-03-27" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "61", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_61_a&doctype=Standard", "URIDate": "2025-03-27" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "61", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_61_b&doctype=Standard", "URIDate": "2025-03-27" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "61", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_61&doctype=Standard", "URIDate": "2025-03-27" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "69", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_69&doctype=Standard", "URIDate": "2025-03-27" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_7&doctype=Standard", "URIDate": "2025-03-27" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard", "URIDate": "2025-03-27" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a&doctype=Standard", "URIDate": "2025-03-27" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_b&doctype=Standard", "URIDate": "2025-03-27" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79&doctype=Standard", "URIDate": "2025-03-27" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_a&doctype=Standard", "URIDate": "2025-03-27" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_b&doctype=Standard", "URIDate": "2025-03-27" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_c&doctype=Standard", "URIDate": "2025-03-27" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81B", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81B_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81B", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81B_b_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_a&doctype=Standard", "URIDate": "2025-03-27" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_b&doctype=Standard", "URIDate": "2025-03-27" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_d&doctype=Standard", "URIDate": "2025-03-27" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "91", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_91_a&doctype=Standard", "URIDate": "2025-03-27" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "99", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_99&doctype=Standard", "URIDate": "2025-03-27" }, "r228": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "138", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_138_a&doctype=Standard", "URIDate": "2025-03-27" }, "r229": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "138", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_138_d&doctype=Standard", "URIDate": "2025-03-27" }, "r230": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "147", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_147_c&doctype=Standard", "URIDate": "2025-03-27" }, "r231": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "32", "IssueDate": "2025-01-01", "Paragraph": "IE33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2025-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2025-03-27" }, "r232": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_127&doctype=Standard", "URIDate": "2025-03-27" }, "r233": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "119", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_119_a&doctype=Standard", "URIDate": "2025-03-27" }, "r234": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "119", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_119_c&doctype=Standard", "URIDate": "2025-03-27" }, "r235": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "119", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_119_e&doctype=Standard", "URIDate": "2025-03-27" }, "r236": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "14", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_14_a&doctype=Standard", "URIDate": "2025-03-27" }, "r237": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "14", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_14_f&doctype=Standard", "URIDate": "2025-03-27" }, "r238": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "16", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16_a&doctype=Standard", "URIDate": "2025-03-27" }, "r239": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2025-03-27" }, "r240": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_c&doctype=Standard", "URIDate": "2025-03-27" }, "r241": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_d&doctype=Standard", "URIDate": "2025-03-27" }, "r242": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2025-03-27" }, "r243": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44D", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44D&doctype=Standard", "URIDate": "2025-03-27" }, "r244": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "IG63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_IG63&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r245": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r246": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "B89", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r247": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "B89", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_B89_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r248": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2025-03-27" }, "r249": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "96", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_96_b&doctype=Standard", "URIDate": "2025-03-27" }, "r250": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "96", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_96_c&doctype=Standard", "URIDate": "2025-03-27" }, "r251": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35N", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35N&doctype=Standard", "URIDate": "2025-03-27" }, "r252": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "40", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_40_a&doctype=Standard", "URIDate": "2025-03-27" }, "r253": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B11", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B11_d&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r254": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B11", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B11&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r255": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B11D", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B11D_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r256": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B11D", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B11D&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r257": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B35", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35_d&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r258": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B35", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r259": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r260": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "IG31A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r261": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "IG32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_IG32&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r262": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard", "URIDate": "2025-03-27" }, "r263": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2025-03-27" }, "r264": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28&doctype=Standard", "URIDate": "2025-03-27" }, "r265": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "IG4", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_IG4&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r266": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "103", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103_b&doctype=Standard", "URIDate": "2025-03-27" }, "r267": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "103", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103_f&doctype=Standard", "URIDate": "2025-03-27" }, "r268": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "251", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_251&doctype=Standard", "URIDate": "2025-03-27" }, "r269": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r270": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_102&doctype=Standard", "URIDate": "2025-03-27" }, "r271": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_103&doctype=Standard", "URIDate": "2025-03-27" }, "r272": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_108&doctype=Standard", "URIDate": "2025-03-27" }, "r273": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "68", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_68&doctype=Standard", "URIDate": "2025-03-27" }, "r274": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r275": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "IG6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r276": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r277": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2025-03-27" }, "r278": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "9", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_9&doctype=Standard", "URIDate": "2025-03-27" }, "r279": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2025-03-27" }, "r280": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_i&doctype=Standard", "URIDate": "2025-03-27" }, "r281": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_vii&doctype=Standard", "URIDate": "2025-03-27" }, "r282": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2025-03-27" }, "r283": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118&doctype=Standard", "URIDate": "2025-03-27" }, "r284": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "119", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_119&doctype=Standard", "URIDate": "2025-03-27" }, "r285": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2025-03-27" }, "r286": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "41", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2025-03-27" }, "r287": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "14", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_14&doctype=Standard", "URIDate": "2025-03-27" }, "r288": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16&doctype=Standard", "URIDate": "2025-03-27" }, "r289": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_7&doctype=Standard", "URIDate": "2025-03-27" }, "r290": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "10", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_10_e&doctype=Standard", "URIDate": "2025-03-27" }, "r291": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_102&doctype=Standard", "URIDate": "2025-03-27" }, "r292": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_103&doctype=Standard", "URIDate": "2025-03-27" }, "r293": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_104&doctype=Standard", "URIDate": "2025-03-27" }, "r294": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d&doctype=Standard", "URIDate": "2025-03-27" }, "r295": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_108&doctype=Standard", "URIDate": "2025-03-27" }, "r296": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "112", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_112_c&doctype=Standard", "URIDate": "2025-03-27" }, "r297": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard", "URIDate": "2025-03-27" }, "r298": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a&doctype=Standard", "URIDate": "2025-03-27" }, "r299": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "85", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_85&doctype=Standard", "URIDate": "2025-03-27" } } }